Reported covered position: N/A
How to read the money
Income and expense are whole-filing amounts associated with this lobbyist, not personal compensation or an allocated share.
No topic inference: each bill number appears in source LDA issue text assigned to this lobbyist.
Mikaela Naylon Give Kids a Chance Act
Client: BIOMARIN PHARMACEUTICAL INC. · Firm: BIOMARIN PHARMACEUTICAL INC.
HR 1262: GIVE KIDS A CHANCE ACT OF 2025; PROVISIONS RELATED TO RARE PEDIATRIC DISEASE PRIORITY REVIEW VOUCHER PROGRAM REAUTHORIZATION S 932: GIVE KIDS A CHANCE ACT OF 2025; PROVISIONS RELATED TO RARE PEDIATRIC DISEASE PRIORITY REVIEW VOUCHER PROGRAM REAUTHORIZATION GENERAL DISCUSSIONS REGARDING INFLATION REDUCTION ACT AND ORPHAN DRUGS GENERAL DISCUSSIONS REGARDING ORPHAN DRUG ACT GENERAL DISCUSSIONS REGARDING GENETIC SCREENING AND NEWBORN SCREENING
Mikaela Naylon Give Kids a Chance Act
Client: BIOMARIN PHARMACEUTICAL INC. · Firm: BIOMARIN PHARMACEUTICAL INC.
Specific issues are shown only where the LDA source assigned them to this lobbyist. Targets apply to the associated filing.
BIOMARIN PHARMACEUTICAL INC. via BIOMARIN PHARMACEUTICAL INC.
2026 · second_quarter · 2A
GENERAL DISCUSSIONS RELATED TO MOST-FAVORED-NATION (MFN) FOREIGN REFERENCE PRICING GENERAL DISCUSSIONS REGARDING MEDICAID PRIOR AUTHORIZATION GENERAL DISCUSSIONS REGARDING UTILIZATION MANAGEMENT
GENERAL DISCUSSIONS REGARDING TARDE
Source: Senate LDA
H.R.1262: GIVE KIDS A CHANCE ACT OF 2025; PROVISIONS RELATED TO RARE PEDIATRIC DISEASE PRIORITY REVIEW VOUCHER PROGRAM REAUTHORIZATION S.932: GIVE KIDS A CHANCE ACT OF 2025; PROVISIONS RELATED TO RARE PEDIATRIC DISEASE PRIORITY REVIEW VOUCHER PROGRAM REAUTHORIZATION GENERAL DISCUSSIONS REGARDING GENETIC SREENING AND NEWBORN SREENING GENERAL DISCUSSIONS REGARDING ORPHAN DRUGS GENERAL DISCUSSIONS RELATED TO MOST-FAVORED-NATION (MFN) DRUG PRICING GENERAL DISCUSSIONS RELATED TO THE PRIORITY REVIEW VOUCHER PROGRAM
Mikaela Naylon Give Kids a Chance Act
Client: BIOMARIN PHARMACEUTICAL INC. · Firm: BIOMARIN PHARMACEUTICAL INC.
H.R.1262: GIVE KIDS A CHANCE ACT OF 2025; PROVISIONS RELATED TO RARE PEDIATRIC DISEASE PRIORITY REVIEW VOUCHER PROGRAM REAUTHORIZATION S.932: GIVE KIDS A CHANCE ACT OF 2025; PROVISIONS RELATED TO RARE PEDIATRIC DISEASE PRIORITY REVIEW VOUCHER PROGRAM REAUTHORIZATION GENERAL DISCUSSIONS REGARDING GENETIC SREENING AND NEWBORN SREENING GENERAL DISCUSSIONS REGARDING ORPHAN DRUGS GENERAL DISCUSSIONS RELATED TO MOST-FAVORED-NATION (MFN) DRUG PRICING GENERAL DISCUSSIONS RELATED TO THE PRIORITY REVIEW VOUCHER PROGRAM
Mikaela Naylon Give Kids a Chance Act
Client: BIOMARIN PHARMACEUTICAL INC. · Firm: BIOMARIN PHARMACEUTICAL INC.
HR 1262: GIVE KIDS A CHANCE ACT OF 2025; PROVISIONS RELATED TO RARE PEDIATRIC DISEASE PRIORITY REVIEW VOUCHER PROGRAM REAUTHORIZATION S 932: GIVE KIDS A CHANCE ACT OF 2025; PROVISIONS RELATED TO RARE PEDIATRIC DISEASE PRIORITY REVIEW VOUCHER PROGRAM REAUTHORIZATION GENERAL DISCUSSIONS REGARDING ORPHAN DRUG ACT, HEALTH AND HUMAN SERVICES (HHS) RESTRUCTURING, MANUFACTURER-SPONSORED GENETIC SCREENING, PRIORITY REVIEW VOUCHER (PRV) EXTENSION, MEDICAID, NEWBORN SCREENING
Give Kids a Chance Act of 2025
Client: BIOMARIN PHARMACEUTICAL INC. · Firm: BIOMARIN PHARMACEUTICAL INC.
H.R.1262: GIVE KIDS A CHANCE ACT OF 2025; PROVISIONS RELATED TO RARE PEDIATRIC DISEASE PRIORITY REVIEW VOUCHER PROGRAM REAUTHORIZATION S.932: GIVE KIDS A CHANCE ACT OF 2025; PROVISIONS RELATED TO RARE PEDIATRIC DISEASE PRIORITY REVIEW VOUCHER PROGRAM REAUTHORIZATION GENERAL DISCUSSIONS REGARDING GENETIC SREENING AND NEWBORN SREENING GENERAL DISCUSSIONS REGARDING ORPHAN DRUGS GENERAL DISCUSSIONS RELATED TO MOST-FAVORED-NATION (MFN) DRUG PRICING GENERAL DISCUSSIONS RELATED TO THE PRIORITY REVIEW VOUCHER PROGRAM
Give Kids a Chance Act of 2025
Client: BIOMARIN PHARMACEUTICAL INC. · Firm: BIOMARIN PHARMACEUTICAL INC.
HR 1262: GIVE KIDS A CHANCE ACT OF 2025; PROVISIONS RELATED TO RARE PEDIATRIC DISEASE PRIORITY REVIEW VOUCHER PROGRAM REAUTHORIZATION S 932: GIVE KIDS A CHANCE ACT OF 2025; PROVISIONS RELATED TO RARE PEDIATRIC DISEASE PRIORITY REVIEW VOUCHER PROGRAM REAUTHORIZATION GENERAL DISCUSSIONS REGARDING INFLATION REDUCTION ACT AND ORPHAN DRUGS GENERAL DISCUSSIONS REGARDING ORPHAN DRUG ACT GENERAL DISCUSSIONS REGARDING GENETIC SCREENING AND NEWBORN SCREENING
Give Kids a Chance Act of 2025
Client: BIOMARIN PHARMACEUTICAL INC. · Firm: BIOMARIN PHARMACEUTICAL INC.
HR 1262: GIVE KIDS A CHANCE ACT OF 2025; PROVISIONS RELATED TO RARE PEDIATRIC DISEASE PRIORITY REVIEW VOUCHER PROGRAM REAUTHORIZATION S 932: GIVE KIDS A CHANCE ACT OF 2025; PROVISIONS RELATED TO RARE PEDIATRIC DISEASE PRIORITY REVIEW VOUCHER PROGRAM REAUTHORIZATION GENERAL DISCUSSIONS REGARDING ORPHAN DRUG ACT, HEALTH AND HUMAN SERVICES (HHS) RESTRUCTURING, MANUFACTURER-SPONSORED GENETIC SCREENING, PRIORITY REVIEW VOUCHER (PRV) EXTENSION, MEDICAID, NEWBORN SCREENING
Give Kids a Chance Act of 2025
Client: BIOMARIN PHARMACEUTICAL INC. · Firm: BIOMARIN PHARMACEUTICAL INC.
H.R.1262: GIVE KIDS A CHANCE ACT OF 2025; PROVISIONS RELATED TO RARE PEDIATRIC DISEASE PRIORITY REVIEW VOUCHER PROGRAM REAUTHORIZATION S.932: GIVE KIDS A CHANCE ACT OF 2025; PROVISIONS RELATED TO RARE PEDIATRIC DISEASE PRIORITY REVIEW VOUCHER PROGRAM REAUTHORIZATION GENERAL DISCUSSIONS REGARDING GENETIC SREENING AND NEWBORN SREENING GENERAL DISCUSSIONS REGARDING ORPHAN DRUGS GENERAL DISCUSSIONS RELATED TO MOST-FAVORED-NATION (MFN) DRUG PRICING GENERAL DISCUSSIONS RELATED TO THE PRIORITY REVIEW VOUCHER PROGRAM
HR 830: HELP ENSURE LOWER PATIENT COPAYS ACT; ALL PROVISIONS OF THE BILL HR 2369: VERIFYING ACCURATE LEADING-EDGE IVCT DEVELOPMENT ACT OF 2023; ALL PROVISIONS OF THE BILL HR 2630: SAFE STEP ACT; ALL PROVISIONS OF THE BILL HR 2666: MEDICAID VBPS FOR PATIENTS ACT (MVP ACT); PROVISIONS RELATED TO OUTCOME BASED ARRANGEMENTS (OBA) AND VALUE BASED ARRANGEMENTS (VBA) HR 5539: OPTIMIZING RESEARCH PROGRESS HOPE AND NEW CURES ACT (ORPHAN CURES ACT); ALL PROVISIONS OF THE BILL HR 7384: CREATING HOPE REAUTHORIZATION ACT OF 2024; ALL PROVISIONS OF THE BILL S 4583: A BILL TO AMEND THE FEDERAL FOOD, DRUG, AND COSMETIC ACT TO EXTEND THE AUTHORITY OF THE SECRETARY OF HEALTH AND HUMAN SERVICES TO ISSUE PRIORITY REVIEW VOUCHERS TO ENCOURAGE TREATMENTS FOR RARE PEDIATRIC DISEASES; ALL PROVISIONS OF THE BILL GENERAL DISCUSSIONS REGARDING HEALTH EQUITY
HR 830: HELP ENSURE LOWER PATIENT (HELP) COPAYS ACT; ALL PROVISIONS OF THE BILL HR 2630: SAFE STEP ACT; ALL PROVISIONS OF THE BILL HR 2666: MEDICAID VBPS FOR PATIENTS ACT (MVP ACT); PROVISIONS RELATED TO OUTCOME BASED ARRANGEMENTS (OBA) AND VALUE BASED ARRANGEMENTS (VBA) HR 7384: CREATING HOPE REAUTHORIZATION ACT OF 2024; ALL PROVISIONS OF THE BILL HR 8574: 340B AFFORDABLE CARE FOR COMMUNITIES AND ENSURING A STRONG SAFETY-NET (ACCESS) ACT; ALL PROVISIONS OF THE BILL HR 9184: PATIENT ACCESS ACT OF 2024; ALL PROVISIONS OF THE BILL S 4583: CREATING HOPE REAUTHORIZATION ACT OF 2024; ALL PROVISIONS OF THE BILL GENERAL DISCUSSIONS REGARDING GENETIC SCREENING, LONG TERM FOLLOW UP, CURES 3.0
HR 830: HELP ENSURE LOWER PATIENT (HELP) COPAYS ACT; ALL PROVISIONS OF THE BILL HR 2630: SAFE STEP ACT; ALL PROVISIONS OF THE BILL HR 2666: MEDICAID VBPS FOR PATIENTS ACT (MVP ACT); PROVISIONS RELATED TO OUTCOME BASED ARRANGEMENTS (OBA) AND VALUE BASED ARRANGEMENTS (VBA) HR 4758: ACCELERATING KIDS' ACCESS TO CARE ACT: ALL PROVISIONS OF THE BILL HR 7384: CREATING HOPE REAUTHORIZATION ACT OF 2024; ALL PROVISIONS OF THE BILL HR 8574: 340B AFFORDABLE CARE FOR COMMUNITIES AND ENSURING A STRONG SAFETY-NET (ACCESS) ACT; ALL PROVISIONS OF THE BILL HR 9184: PATIENT ACCESS ACT OF 2024; ALL PROVISIONS OF THE BILL S 2372: ACCELERATING KIDS' ACCESS TO CARE ACT; ALL PROVISIONS OF THE BILL S 4583: CREATING HOPE REAUTHORIZATION ACT OF 2024; ALL PROVISIONS OF THE BILL GENERAL DISCUSSIONS REGARDING GENETIC SCREENING, LONG TERM FOLLOW UP, CURES 3.0, AND ORPHAN DRUG ACT
HR 830: HELP ENSURE LOWER PATIENT COPAYS ACT; ALL PROVISIONS OF THE BILL HR 2369: VERIFYING ACCURATE LEADING-EDGE IVCT DEVELOPMENT ACT OF 2023; ALL PROVISIONS OF THE BILL HR 2630: SAFE STEP ACT; ALL PROVISIONS OF THE BILL HR 2666: MEDICAID VBPS FOR PATIENTS ACT (MVP ACT); PROVISIONS RELATED TO OUTCOME BASED ARRANGEMENTS (OBA) AND VALUE BASED ARRANGEMENTS (VBA) HR 5539: OPTIMIZING RESEARCH PROGRESS HOPE AND NEW CURES ACT (ORPHAN CURES ACT); ALL PROVISIONS OF THE BILL HR 7384: CREATING HOPE REAUTHORIZATION ACT OF 2024; ALL PROVISIONS OF THE BILL S 4583: A BILL TO AMEND THE FEDERAL FOOD, DRUG, AND COSMETIC ACT TO EXTEND THE AUTHORITY OF THE SECRETARY OF HEALTH AND HUMAN SERVICES TO ISSUE PRIORITY REVIEW VOUCHERS TO ENCOURAGE TREATMENTS FOR RARE PEDIATRIC DISEASES; ALL PROVISIONS OF THE BILL GENERAL DISCUSSIONS REGARDING HEALTH EQUITY
Medicaid VBPs for Patients Act
Client: BIOMARIN PHARMACEUTICAL INC. · Firm: BIOMARIN PHARMACEUTICAL INC.
HR 830: HELP ENSURE LOWER PATIENT (HELP) COPAYS ACT; ALL PROVISIONS OF THE BILL HR 2630: SAFE STEP ACT; ALL PROVISIONS OF THE BILL HR 2666: MEDICAID VBPS FOR PATIENTS ACT (MVP ACT); PROVISIONS RELATED TO OUTCOME BASED ARRANGEMENTS (OBA) AND VALUE BASED ARRANGEMENTS (VBA) HR 7384: CREATING HOPE REAUTHORIZATION ACT OF 2024; ALL PROVISIONS OF THE BILL HR 8574: 340B AFFORDABLE CARE FOR COMMUNITIES AND ENSURING A STRONG SAFETY-NET (ACCESS) ACT; ALL PROVISIONS OF THE BILL HR 9184: PATIENT ACCESS ACT OF 2024; ALL PROVISIONS OF THE BILL S 4583: CREATING HOPE REAUTHORIZATION ACT OF 2024; ALL PROVISIONS OF THE BILL GENERAL DISCUSSIONS REGARDING GENETIC SCREENING, LONG TERM FOLLOW UP, CURES 3.0
Medicaid VBPs for Patients Act
Client: BIOMARIN PHARMACEUTICAL INC. · Firm: BIOMARIN PHARMACEUTICAL INC.
HR 830: HELP ENSURE LOWER PATIENT COPAYS ACT; ALL PROVISIONS OF THE BILL HR 2369: VERIFYING ACCURATE LEADING-EDGE IVCT DEVELOPMENT ACT OF 2023; ALL PROVISIONS OF THE BILL HR 2630: SAFE STEP ACT; ALL PROVISIONS OF THE BILL HR 2666: MEDICAID VBPS FOR PATIENTS ACT (MVP ACT); PROVISIONS RELATED TO OUTCOME BASED ARRANGEMENTS (OBA) AND VALUE BASED ARRANGEMENTS (VBA) HR 5539: OPTIMIZING RESEARCH PROGRESS HOPE AND NEW CURES ACT (ORPHAN CURES ACT); ALL PROVISIONS OF THE BILL HR 7384: CREATING HOPE REAUTHORIZATION ACT OF 2024; ALL PROVISIONS OF THE BILL S 4583: A BILL TO AMEND THE FEDERAL FOOD, DRUG, AND COSMETIC ACT TO EXTEND THE AUTHORITY OF THE SECRETARY OF HEALTH AND HUMAN SERVICES TO ISSUE PRIORITY REVIEW VOUCHERS TO ENCOURAGE TREATMENTS FOR RARE PEDIATRIC DISEASES; ALL PROVISIONS OF THE BILL GENERAL DISCUSSIONS REGARDING HEALTH EQUITY
Medicaid VBPs for Patients Act
Client: BIOMARIN PHARMACEUTICAL INC. · Firm: BIOMARIN PHARMACEUTICAL INC.
HR 830: HELP ENSURE LOWER PATIENT (HELP) COPAYS ACT; ALL PROVISIONS OF THE BILL HR 2630: SAFE STEP ACT; ALL PROVISIONS OF THE BILL HR 2666: MEDICAID VBPS FOR PATIENTS ACT (MVP ACT); PROVISIONS RELATED TO OUTCOME BASED ARRANGEMENTS (OBA) AND VALUE BASED ARRANGEMENTS (VBA) HR 4758: ACCELERATING KIDS' ACCESS TO CARE ACT: ALL PROVISIONS OF THE BILL HR 7384: CREATING HOPE REAUTHORIZATION ACT OF 2024; ALL PROVISIONS OF THE BILL HR 8574: 340B AFFORDABLE CARE FOR COMMUNITIES AND ENSURING A STRONG SAFETY-NET (ACCESS) ACT; ALL PROVISIONS OF THE BILL HR 9184: PATIENT ACCESS ACT OF 2024; ALL PROVISIONS OF THE BILL S 2372: ACCELERATING KIDS' ACCESS TO CARE ACT; ALL PROVISIONS OF THE BILL S 4583: CREATING HOPE REAUTHORIZATION ACT OF 2024; ALL PROVISIONS OF THE BILL GENERAL DISCUSSIONS REGARDING GENETIC SCREENING, LONG TERM FOLLOW UP, CURES 3.0, AND ORPHAN DRUG ACT
Medicaid VBPs for Patients Act
Client: BIOMARIN PHARMACEUTICAL INC. · Firm: BIOMARIN PHARMACEUTICAL INC.
HR 2666: MEDICAID VBPS FOR PATIENTS ACT (MVP ACT); PROVISIONS RELATED TO OUTCOME BASED ARRANGEMENTS (OBA) AND VALUE BASED ARRANGEMENTS (VBA) HR 5539: OPTIMIZING RESEARCH PROGRESS HOPE AND NEW CURES ACT (ORPHAN CURES ACT); ALL PROVISIONS OF THE BILL HR 7384: CREATING HOPE REAUTHORIZATION ACT OF 2024: ALL PROVISIONS OF THE BILL HR 7635: THE 340B PHARMACEUTICAL ACCESS TO INVEST IN ESSENTIAL, NEEDED TREATMENTS & SUPPORT ACT OF 2024 (PATIENTS ACT); ALL PROVISIONS OF THE BILL GENERAL DISCUSSIONS REGARDING HEMOPHILIA GENE THERAPY
Accelerating Kids’ Access to Care Act
Client: BIOMARIN PHARMACEUTICAL INC. · Firm: BIOMARIN PHARMACEUTICAL INC.
HR 830: HELP ENSURE LOWER PATIENT (HELP) COPAYS ACT; ALL PROVISIONS OF THE BILL HR 2630: SAFE STEP ACT; ALL PROVISIONS OF THE BILL HR 2666: MEDICAID VBPS FOR PATIENTS ACT (MVP ACT); PROVISIONS RELATED TO OUTCOME BASED ARRANGEMENTS (OBA) AND VALUE BASED ARRANGEMENTS (VBA) HR 4758: ACCELERATING KIDS' ACCESS TO CARE ACT: ALL PROVISIONS OF THE BILL HR 7384: CREATING HOPE REAUTHORIZATION ACT OF 2024; ALL PROVISIONS OF THE BILL HR 8574: 340B AFFORDABLE CARE FOR COMMUNITIES AND ENSURING A STRONG SAFETY-NET (ACCESS) ACT; ALL PROVISIONS OF THE BILL HR 9184: PATIENT ACCESS ACT OF 2024; ALL PROVISIONS OF THE BILL S 2372: ACCELERATING KIDS' ACCESS TO CARE ACT; ALL PROVISIONS OF THE BILL S 4583: CREATING HOPE REAUTHORIZATION ACT OF 2024; ALL PROVISIONS OF THE BILL GENERAL DISCUSSIONS REGARDING GENETIC SCREENING, LONG TERM FOLLOW UP, CURES 3.0, AND ORPHAN DRUG ACT
HR 2666: MEDICAID VBPS FOR PATIENTS ACT (MVP ACT); PROVISIONS RELATED TO OUTCOME BASED ARRANGEMENTS (OBA) AND VALUE BASED ARRANGEMENTS (VBA) HR 5539: OPTIMIZING RESEARCH PROGRESS HOPE AND NEW CURES ACT (ORPHAN CURES ACT); ALL PROVISIONS OF THE BILL HR 7384: CREATING HOPE REAUTHORIZATION ACT OF 2024: ALL PROVISIONS OF THE BILL HR 7635: THE 340B PHARMACEUTICAL ACCESS TO INVEST IN ESSENTIAL, NEEDED TREATMENTS & SUPPORT ACT OF 2024 (PATIENTS ACT); ALL PROVISIONS OF THE BILL GENERAL DISCUSSIONS REGARDING HEMOPHILIA GENE THERAPY
HR 830: HELP ENSURE LOWER PATIENT COPAYS ACT; ALL PROVISIONS OF THE BILL HR 2369: VERIFYING ACCURATE LEADING-EDGE IVCT DEVELOPMENT ACT OF 2023; ALL PROVISIONS OF THE BILL HR 2630: SAFE STEP ACT; ALL PROVISIONS OF THE BILL HR 2666: MEDICAID VBPS FOR PATIENTS ACT (MVP ACT); PROVISIONS RELATED TO OUTCOME BASED ARRANGEMENTS (OBA) AND VALUE BASED ARRANGEMENTS (VBA) HR 5539: OPTIMIZING RESEARCH PROGRESS HOPE AND NEW CURES ACT (ORPHAN CURES ACT); ALL PROVISIONS OF THE BILL HR 7384: CREATING HOPE REAUTHORIZATION ACT OF 2024; ALL PROVISIONS OF THE BILL S 4583: A BILL TO AMEND THE FEDERAL FOOD, DRUG, AND COSMETIC ACT TO EXTEND THE AUTHORITY OF THE SECRETARY OF HEALTH AND HUMAN SERVICES TO ISSUE PRIORITY REVIEW VOUCHERS TO ENCOURAGE TREATMENTS FOR RARE PEDIATRIC DISEASES; ALL PROVISIONS OF THE BILL GENERAL DISCUSSIONS REGARDING HEALTH EQUITY
Creating Hope Reauthorization Act of 2024
Client: BIOMARIN PHARMACEUTICAL INC. · Firm: BIOMARIN PHARMACEUTICAL INC.
HR 830: HELP ENSURE LOWER PATIENT (HELP) COPAYS ACT; ALL PROVISIONS OF THE BILL HR 2630: SAFE STEP ACT; ALL PROVISIONS OF THE BILL HR 2666: MEDICAID VBPS FOR PATIENTS ACT (MVP ACT); PROVISIONS RELATED TO OUTCOME BASED ARRANGEMENTS (OBA) AND VALUE BASED ARRANGEMENTS (VBA) HR 4758: ACCELERATING KIDS' ACCESS TO CARE ACT: ALL PROVISIONS OF THE BILL HR 7384: CREATING HOPE REAUTHORIZATION ACT OF 2024; ALL PROVISIONS OF THE BILL HR 8574: 340B AFFORDABLE CARE FOR COMMUNITIES AND ENSURING A STRONG SAFETY-NET (ACCESS) ACT; ALL PROVISIONS OF THE BILL HR 9184: PATIENT ACCESS ACT OF 2024; ALL PROVISIONS OF THE BILL S 2372: ACCELERATING KIDS' ACCESS TO CARE ACT; ALL PROVISIONS OF THE BILL S 4583: CREATING HOPE REAUTHORIZATION ACT OF 2024; ALL PROVISIONS OF THE BILL GENERAL DISCUSSIONS REGARDING GENETIC SCREENING, LONG TERM FOLLOW UP, CURES 3.0, AND ORPHAN DRUG ACT
Creating Hope Reauthorization Act of 2024
Client: BIOMARIN PHARMACEUTICAL INC. · Firm: BIOMARIN PHARMACEUTICAL INC.
HR 830: HELP ENSURE LOWER PATIENT COPAYS ACT; ALL PROVISIONS OF THE BILL HR 2369: VERIFYING ACCURATE LEADING-EDGE IVCT DEVELOPMENT ACT OF 2023; ALL PROVISIONS OF THE BILL HR 2630: SAFE STEP ACT; ALL PROVISIONS OF THE BILL HR 2666: MEDICAID VBPS FOR PATIENTS ACT (MVP ACT); PROVISIONS RELATED TO OUTCOME BASED ARRANGEMENTS (OBA) AND VALUE BASED ARRANGEMENTS (VBA) HR 5539: OPTIMIZING RESEARCH PROGRESS HOPE AND NEW CURES ACT (ORPHAN CURES ACT); ALL PROVISIONS OF THE BILL HR 7384: CREATING HOPE REAUTHORIZATION ACT OF 2024; ALL PROVISIONS OF THE BILL S 4583: A BILL TO AMEND THE FEDERAL FOOD, DRUG, AND COSMETIC ACT TO EXTEND THE AUTHORITY OF THE SECRETARY OF HEALTH AND HUMAN SERVICES TO ISSUE PRIORITY REVIEW VOUCHERS TO ENCOURAGE TREATMENTS FOR RARE PEDIATRIC DISEASES; ALL PROVISIONS OF THE BILL GENERAL DISCUSSIONS REGARDING HEALTH EQUITY
Creating Hope Reauthorization Act of 2024
Client: BIOMARIN PHARMACEUTICAL INC. · Firm: BIOMARIN PHARMACEUTICAL INC.
HR 2666: MEDICAID VBPS FOR PATIENTS ACT (MVP ACT); PROVISIONS RELATED TO OUTCOME BASED ARRANGEMENTS (OBA) AND VALUE BASED ARRANGEMENTS (VBA) HR 5539: OPTIMIZING RESEARCH PROGRESS HOPE AND NEW CURES ACT (ORPHAN CURES ACT); ALL PROVISIONS OF THE BILL HR 7384: CREATING HOPE REAUTHORIZATION ACT OF 2024: ALL PROVISIONS OF THE BILL HR 7635: THE 340B PHARMACEUTICAL ACCESS TO INVEST IN ESSENTIAL, NEEDED TREATMENTS & SUPPORT ACT OF 2024 (PATIENTS ACT); ALL PROVISIONS OF THE BILL GENERAL DISCUSSIONS REGARDING HEMOPHILIA GENE THERAPY
Creating Hope Reauthorization Act of 2024
Client: BIOMARIN PHARMACEUTICAL INC. · Firm: BIOMARIN PHARMACEUTICAL INC.
HR 830: HELP ENSURE LOWER PATIENT (HELP) COPAYS ACT; ALL PROVISIONS OF THE BILL HR 2630: SAFE STEP ACT; ALL PROVISIONS OF THE BILL HR 2666: MEDICAID VBPS FOR PATIENTS ACT (MVP ACT); PROVISIONS RELATED TO OUTCOME BASED ARRANGEMENTS (OBA) AND VALUE BASED ARRANGEMENTS (VBA) HR 7384: CREATING HOPE REAUTHORIZATION ACT OF 2024; ALL PROVISIONS OF THE BILL HR 8574: 340B AFFORDABLE CARE FOR COMMUNITIES AND ENSURING A STRONG SAFETY-NET (ACCESS) ACT; ALL PROVISIONS OF THE BILL HR 9184: PATIENT ACCESS ACT OF 2024; ALL PROVISIONS OF THE BILL S 4583: CREATING HOPE REAUTHORIZATION ACT OF 2024; ALL PROVISIONS OF THE BILL GENERAL DISCUSSIONS REGARDING GENETIC SCREENING, LONG TERM FOLLOW UP, CURES 3.0
The 340B PATIENTS Act of 2024
Client: BIOMARIN PHARMACEUTICAL INC. · Firm: BIOMARIN PHARMACEUTICAL INC.
HR 2666: MEDICAID VBPS FOR PATIENTS ACT (MVP ACT); PROVISIONS RELATED TO OUTCOME BASED ARRANGEMENTS (OBA) AND VALUE BASED ARRANGEMENTS (VBA) HR 5539: OPTIMIZING RESEARCH PROGRESS HOPE AND NEW CURES ACT (ORPHAN CURES ACT); ALL PROVISIONS OF THE BILL HR 7384: CREATING HOPE REAUTHORIZATION ACT OF 2024: ALL PROVISIONS OF THE BILL HR 7635: THE 340B PHARMACEUTICAL ACCESS TO INVEST IN ESSENTIAL, NEEDED TREATMENTS & SUPPORT ACT OF 2024 (PATIENTS ACT); ALL PROVISIONS OF THE BILL GENERAL DISCUSSIONS REGARDING HEMOPHILIA GENE THERAPY
HR 830: HELP ENSURE LOWER PATIENT (HELP) COPAYS ACT; ALL PROVISIONS OF THE BILL HR 2630: SAFE STEP ACT; ALL PROVISIONS OF THE BILL HR 2666: MEDICAID VBPS FOR PATIENTS ACT (MVP ACT); PROVISIONS RELATED TO OUTCOME BASED ARRANGEMENTS (OBA) AND VALUE BASED ARRANGEMENTS (VBA) HR 4758: ACCELERATING KIDS' ACCESS TO CARE ACT: ALL PROVISIONS OF THE BILL HR 7384: CREATING HOPE REAUTHORIZATION ACT OF 2024; ALL PROVISIONS OF THE BILL HR 8574: 340B AFFORDABLE CARE FOR COMMUNITIES AND ENSURING A STRONG SAFETY-NET (ACCESS) ACT; ALL PROVISIONS OF THE BILL HR 9184: PATIENT ACCESS ACT OF 2024; ALL PROVISIONS OF THE BILL S 2372: ACCELERATING KIDS' ACCESS TO CARE ACT; ALL PROVISIONS OF THE BILL S 4583: CREATING HOPE REAUTHORIZATION ACT OF 2024; ALL PROVISIONS OF THE BILL GENERAL DISCUSSIONS REGARDING GENETIC SCREENING, LONG TERM FOLLOW UP, CURES 3.0, AND ORPHAN DRUG ACT
HR 830: HELP ENSURE LOWER PATIENT COPAYS ACT; ALL PROVISIONS OF THE BILL HR 2369: VERIFYING ACCURATE LEADING-EDGE IVCT DEVELOPMENT ACT OF 2023; ALL PROVISIONS OF THE BILL HR 2630: SAFE STEP ACT; ALL PROVISIONS OF THE BILL HR 2666: MEDICAID VBPS FOR PATIENTS ACT (MVP ACT); PROVISIONS RELATED TO OUTCOME BASED ARRANGEMENTS (OBA) AND VALUE BASED ARRANGEMENTS (VBA) HR 5539: OPTIMIZING RESEARCH PROGRESS HOPE AND NEW CURES ACT (ORPHAN CURES ACT); ALL PROVISIONS OF THE BILL HR 7384: CREATING HOPE REAUTHORIZATION ACT OF 2024; ALL PROVISIONS OF THE BILL S 4583: A BILL TO AMEND THE FEDERAL FOOD, DRUG, AND COSMETIC ACT TO EXTEND THE AUTHORITY OF THE SECRETARY OF HEALTH AND HUMAN SERVICES TO ISSUE PRIORITY REVIEW VOUCHERS TO ENCOURAGE TREATMENTS FOR RARE PEDIATRIC DISEASES; ALL PROVISIONS OF THE BILL GENERAL DISCUSSIONS REGARDING HEALTH EQUITY
HR 830: HELP ENSURE LOWER PATIENT (HELP) COPAYS ACT; ALL PROVISIONS OF THE BILL HR 2630: SAFE STEP ACT; ALL PROVISIONS OF THE BILL HR 2666: MEDICAID VBPS FOR PATIENTS ACT (MVP ACT); PROVISIONS RELATED TO OUTCOME BASED ARRANGEMENTS (OBA) AND VALUE BASED ARRANGEMENTS (VBA) HR 7384: CREATING HOPE REAUTHORIZATION ACT OF 2024; ALL PROVISIONS OF THE BILL HR 8574: 340B AFFORDABLE CARE FOR COMMUNITIES AND ENSURING A STRONG SAFETY-NET (ACCESS) ACT; ALL PROVISIONS OF THE BILL HR 9184: PATIENT ACCESS ACT OF 2024; ALL PROVISIONS OF THE BILL S 4583: CREATING HOPE REAUTHORIZATION ACT OF 2024; ALL PROVISIONS OF THE BILL GENERAL DISCUSSIONS REGARDING GENETIC SCREENING, LONG TERM FOLLOW UP, CURES 3.0
HR 830: HELP ENSURE LOWER PATIENT (HELP) COPAYS ACT; ALL PROVISIONS OF THE BILL HR 2630: SAFE STEP ACT; ALL PROVISIONS OF THE BILL HR 2666: MEDICAID VBPS FOR PATIENTS ACT (MVP ACT); PROVISIONS RELATED TO OUTCOME BASED ARRANGEMENTS (OBA) AND VALUE BASED ARRANGEMENTS (VBA) HR 4758: ACCELERATING KIDS' ACCESS TO CARE ACT: ALL PROVISIONS OF THE BILL HR 7384: CREATING HOPE REAUTHORIZATION ACT OF 2024; ALL PROVISIONS OF THE BILL HR 8574: 340B AFFORDABLE CARE FOR COMMUNITIES AND ENSURING A STRONG SAFETY-NET (ACCESS) ACT; ALL PROVISIONS OF THE BILL HR 9184: PATIENT ACCESS ACT OF 2024; ALL PROVISIONS OF THE BILL S 2372: ACCELERATING KIDS' ACCESS TO CARE ACT; ALL PROVISIONS OF THE BILL S 4583: CREATING HOPE REAUTHORIZATION ACT OF 2024; ALL PROVISIONS OF THE BILL GENERAL DISCUSSIONS REGARDING GENETIC SCREENING, LONG TERM FOLLOW UP, CURES 3.0, AND ORPHAN DRUG ACT
HR 830: HELP ENSURE LOWER PATIENT (HELP) COPAYS ACT; ALL PROVISIONS OF THE BILL HR 2630: SAFE STEP ACT; ALL PROVISIONS OF THE BILL HR 2666: MEDICAID VBPS FOR PATIENTS ACT (MVP ACT); PROVISIONS RELATED TO OUTCOME BASED ARRANGEMENTS (OBA) AND VALUE BASED ARRANGEMENTS (VBA) HR 7384: CREATING HOPE REAUTHORIZATION ACT OF 2024; ALL PROVISIONS OF THE BILL HR 8574: 340B AFFORDABLE CARE FOR COMMUNITIES AND ENSURING A STRONG SAFETY-NET (ACCESS) ACT; ALL PROVISIONS OF THE BILL HR 9184: PATIENT ACCESS ACT OF 2024; ALL PROVISIONS OF THE BILL S 4583: CREATING HOPE REAUTHORIZATION ACT OF 2024; ALL PROVISIONS OF THE BILL GENERAL DISCUSSIONS REGARDING GENETIC SCREENING, LONG TERM FOLLOW UP, CURES 3.0
Patient Access Act of 2024
Client: BIOMARIN PHARMACEUTICAL INC. · Firm: BIOMARIN PHARMACEUTICAL INC.
HR 830: HELP ENSURE LOWER PATIENT (HELP) COPAYS ACT; ALL PROVISIONS OF THE BILL HR 2630: SAFE STEP ACT; ALL PROVISIONS OF THE BILL HR 2666: MEDICAID VBPS FOR PATIENTS ACT (MVP ACT); PROVISIONS RELATED TO OUTCOME BASED ARRANGEMENTS (OBA) AND VALUE BASED ARRANGEMENTS (VBA) HR 4758: ACCELERATING KIDS' ACCESS TO CARE ACT: ALL PROVISIONS OF THE BILL HR 7384: CREATING HOPE REAUTHORIZATION ACT OF 2024; ALL PROVISIONS OF THE BILL HR 8574: 340B AFFORDABLE CARE FOR COMMUNITIES AND ENSURING A STRONG SAFETY-NET (ACCESS) ACT; ALL PROVISIONS OF THE BILL HR 9184: PATIENT ACCESS ACT OF 2024; ALL PROVISIONS OF THE BILL S 2372: ACCELERATING KIDS' ACCESS TO CARE ACT; ALL PROVISIONS OF THE BILL S 4583: CREATING HOPE REAUTHORIZATION ACT OF 2024; ALL PROVISIONS OF THE BILL GENERAL DISCUSSIONS REGARDING GENETIC SCREENING, LONG TERM FOLLOW UP, CURES 3.0, AND ORPHAN DRUG ACT
Patient Access Act of 2024
Client: BIOMARIN PHARMACEUTICAL INC. · Firm: BIOMARIN PHARMACEUTICAL INC.
HR 830: HELP ENSURE LOWER PATIENT (HELP) COPAYS ACT; ALL PROVISIONS OF THE BILL HR 2630: SAFE STEP ACT; ALL PROVISIONS OF THE BILL HR 2666: MEDICAID VBPS FOR PATIENTS ACT (MVP ACT); PROVISIONS RELATED TO OUTCOME BASED ARRANGEMENTS (OBA) AND VALUE BASED ARRANGEMENTS (VBA) HR 7384: CREATING HOPE REAUTHORIZATION ACT OF 2024; ALL PROVISIONS OF THE BILL HR 8574: 340B AFFORDABLE CARE FOR COMMUNITIES AND ENSURING A STRONG SAFETY-NET (ACCESS) ACT; ALL PROVISIONS OF THE BILL HR 9184: PATIENT ACCESS ACT OF 2024; ALL PROVISIONS OF THE BILL S 4583: CREATING HOPE REAUTHORIZATION ACT OF 2024; ALL PROVISIONS OF THE BILL GENERAL DISCUSSIONS REGARDING GENETIC SCREENING, LONG TERM FOLLOW UP, CURES 3.0
Accelerating Kids’ Access to Care Act
Client: BIOMARIN PHARMACEUTICAL INC. · Firm: BIOMARIN PHARMACEUTICAL INC.
HR 830: HELP ENSURE LOWER PATIENT (HELP) COPAYS ACT; ALL PROVISIONS OF THE BILL HR 2630: SAFE STEP ACT; ALL PROVISIONS OF THE BILL HR 2666: MEDICAID VBPS FOR PATIENTS ACT (MVP ACT); PROVISIONS RELATED TO OUTCOME BASED ARRANGEMENTS (OBA) AND VALUE BASED ARRANGEMENTS (VBA) HR 4758: ACCELERATING KIDS' ACCESS TO CARE ACT: ALL PROVISIONS OF THE BILL HR 7384: CREATING HOPE REAUTHORIZATION ACT OF 2024; ALL PROVISIONS OF THE BILL HR 8574: 340B AFFORDABLE CARE FOR COMMUNITIES AND ENSURING A STRONG SAFETY-NET (ACCESS) ACT; ALL PROVISIONS OF THE BILL HR 9184: PATIENT ACCESS ACT OF 2024; ALL PROVISIONS OF THE BILL S 2372: ACCELERATING KIDS' ACCESS TO CARE ACT; ALL PROVISIONS OF THE BILL S 4583: CREATING HOPE REAUTHORIZATION ACT OF 2024; ALL PROVISIONS OF THE BILL GENERAL DISCUSSIONS REGARDING GENETIC SCREENING, LONG TERM FOLLOW UP, CURES 3.0, AND ORPHAN DRUG ACT
Creating Hope Reauthorization Act of 2024
Client: BIOMARIN PHARMACEUTICAL INC. · Firm: BIOMARIN PHARMACEUTICAL INC.
HR 830: HELP ENSURE LOWER PATIENT (HELP) COPAYS ACT; ALL PROVISIONS OF THE BILL HR 2630: SAFE STEP ACT; ALL PROVISIONS OF THE BILL HR 2666: MEDICAID VBPS FOR PATIENTS ACT (MVP ACT); PROVISIONS RELATED TO OUTCOME BASED ARRANGEMENTS (OBA) AND VALUE BASED ARRANGEMENTS (VBA) HR 4758: ACCELERATING KIDS' ACCESS TO CARE ACT: ALL PROVISIONS OF THE BILL HR 7384: CREATING HOPE REAUTHORIZATION ACT OF 2024; ALL PROVISIONS OF THE BILL HR 8574: 340B AFFORDABLE CARE FOR COMMUNITIES AND ENSURING A STRONG SAFETY-NET (ACCESS) ACT; ALL PROVISIONS OF THE BILL HR 9184: PATIENT ACCESS ACT OF 2024; ALL PROVISIONS OF THE BILL S 2372: ACCELERATING KIDS' ACCESS TO CARE ACT; ALL PROVISIONS OF THE BILL S 4583: CREATING HOPE REAUTHORIZATION ACT OF 2024; ALL PROVISIONS OF THE BILL GENERAL DISCUSSIONS REGARDING GENETIC SCREENING, LONG TERM FOLLOW UP, CURES 3.0, AND ORPHAN DRUG ACT
Creating Hope Reauthorization Act of 2024
Client: BIOMARIN PHARMACEUTICAL INC. · Firm: BIOMARIN PHARMACEUTICAL INC.
HR 830: HELP ENSURE LOWER PATIENT COPAYS ACT; ALL PROVISIONS OF THE BILL HR 2369: VERIFYING ACCURATE LEADING-EDGE IVCT DEVELOPMENT ACT OF 2023; ALL PROVISIONS OF THE BILL HR 2630: SAFE STEP ACT; ALL PROVISIONS OF THE BILL HR 2666: MEDICAID VBPS FOR PATIENTS ACT (MVP ACT); PROVISIONS RELATED TO OUTCOME BASED ARRANGEMENTS (OBA) AND VALUE BASED ARRANGEMENTS (VBA) HR 5539: OPTIMIZING RESEARCH PROGRESS HOPE AND NEW CURES ACT (ORPHAN CURES ACT); ALL PROVISIONS OF THE BILL HR 7384: CREATING HOPE REAUTHORIZATION ACT OF 2024; ALL PROVISIONS OF THE BILL S 4583: A BILL TO AMEND THE FEDERAL FOOD, DRUG, AND COSMETIC ACT TO EXTEND THE AUTHORITY OF THE SECRETARY OF HEALTH AND HUMAN SERVICES TO ISSUE PRIORITY REVIEW VOUCHERS TO ENCOURAGE TREATMENTS FOR RARE PEDIATRIC DISEASES; ALL PROVISIONS OF THE BILL GENERAL DISCUSSIONS REGARDING HEALTH EQUITY
Creating Hope Reauthorization Act of 2024
Client: BIOMARIN PHARMACEUTICAL INC. · Firm: BIOMARIN PHARMACEUTICAL INC.
HR 830: HELP ENSURE LOWER PATIENT (HELP) COPAYS ACT; ALL PROVISIONS OF THE BILL HR 2630: SAFE STEP ACT; ALL PROVISIONS OF THE BILL HR 2666: MEDICAID VBPS FOR PATIENTS ACT (MVP ACT); PROVISIONS RELATED TO OUTCOME BASED ARRANGEMENTS (OBA) AND VALUE BASED ARRANGEMENTS (VBA) HR 7384: CREATING HOPE REAUTHORIZATION ACT OF 2024; ALL PROVISIONS OF THE BILL HR 8574: 340B AFFORDABLE CARE FOR COMMUNITIES AND ENSURING A STRONG SAFETY-NET (ACCESS) ACT; ALL PROVISIONS OF THE BILL HR 9184: PATIENT ACCESS ACT OF 2024; ALL PROVISIONS OF THE BILL S 4583: CREATING HOPE REAUTHORIZATION ACT OF 2024; ALL PROVISIONS OF THE BILL GENERAL DISCUSSIONS REGARDING GENETIC SCREENING, LONG TERM FOLLOW UP, CURES 3.0
HR 2369: VALID ACT OF 2023; ALL PROVISIONS OF THE BILL HR 2666: MEDICAID VBPS FOR PATIENTS ACT (MVP ACT); PROVISIONS RELATED TO OUTCOME BASED ARRANGEMENTS (OBA) AND VALUE BASED ARRANGEMENTS (VBA) HR 4408: PROMISING PATHWAY ACT; ALL PROVISIONS OF THE BILL S 1906: PROMISING PATHWAY ACT; ALL PROVISIONS OF THE BILL GENERAL DISCUSSIONS REGARDING 340B DRUG PRICING PROGRAM REFORM, RARE DISEASE GENE THERAPY ACCESS, CENTERS FOR MEDICARE & MEDICAID SERVICES (CMS) PROPOSED PRICE JUSTIFICATION SURVEY, HEMOPHILIA GENE THERAPY, RARE DISEASE DRUG DEVELOPMENT
Medicaid VBPs for Patients Act
Client: BIOMARIN PHARMACEUTICAL INC. · Firm: BIOMARIN PHARMACEUTICAL INC.
HR 2369: VALID ACT OF 2023; ALL PROVISIONS OF THE BILL HR 2666: MEDICAID VBPS FOR PATIENTS ACT (MVP ACT); PROVISIONS RELATED TO OUTCOME BASED ARRANGEMENTS (OBA) AND VALUE BASED ARRANGEMENTS (VBA) HR 4408: PROMISING PATHWAY ACT; ALL PROVISIONS OF THE BILL S 1906: PROMISING PATHWAY ACT; ALL PROVISIONS OF THE BILL GENERAL DISCUSSIONS REGARDING 340B DRUG PRICING PROGRAM REFORM, RARE DISEASE GENE THERAPY ACCESS, CENTERS FOR MEDICARE & MEDICAID SERVICES (CMS) PROPOSED PRICE JUSTIFICATION SURVEY, HEMOPHILIA GENE THERAPY, RARE DISEASE DRUG DEVELOPMENT
Promising Pathway Act
Client: BIOMARIN PHARMACEUTICAL INC. · Firm: BIOMARIN PHARMACEUTICAL INC.
HR 2369: VALID ACT OF 2023; ALL PROVISIONS OF THE BILL HR 2666: MEDICAID VBPS FOR PATIENTS ACT (MVP ACT); PROVISIONS RELATED TO OUTCOME BASED ARRANGEMENTS (OBA) AND VALUE BASED ARRANGEMENTS (VBA) HR 4408: PROMISING PATHWAY ACT; ALL PROVISIONS OF THE BILL S 1906: PROMISING PATHWAY ACT; ALL PROVISIONS OF THE BILL GENERAL DISCUSSIONS REGARDING 340B DRUG PRICING PROGRAM REFORM, RARE DISEASE GENE THERAPY ACCESS, CENTERS FOR MEDICARE & MEDICAID SERVICES (CMS) PROPOSED PRICE JUSTIFICATION SURVEY, HEMOPHILIA GENE THERAPY, RARE DISEASE DRUG DEVELOPMENT
Promising Pathway Act
Client: BIOMARIN PHARMACEUTICAL INC. · Firm: BIOMARIN PHARMACEUTICAL INC.
HR 2369: VALID ACT OF 2023; ALL PROVISIONS OF THE BILL HR 2666: MEDICAID VBPS FOR PATIENTS ACT (MVP ACT); PROVISIONS RELATED TO OUTCOME BASED ARRANGEMENTS (OBA) AND VALUE BASED ARRANGEMENTS (VBA) HR 4408: PROMISING PATHWAY ACT; ALL PROVISIONS OF THE BILL S 1906: PROMISING PATHWAY ACT; ALL PROVISIONS OF THE BILL GENERAL DISCUSSIONS REGARDING 340B DRUG PRICING PROGRAM REFORM, RARE DISEASE GENE THERAPY ACCESS, CENTERS FOR MEDICARE & MEDICAID SERVICES (CMS) PROPOSED PRICE JUSTIFICATION SURVEY, HEMOPHILIA GENE THERAPY, RARE DISEASE DRUG DEVELOPMENT
Consolidated Appropriations Act, 2023
Client: BIOMARIN PHARMACEUTICAL INC. · Firm: BIOMARIN PHARMACEUTICAL INC.
HR 482: NEWBORN SCREENING SAVES LIVES REAUTHORIZATION ACT OF 2021; ALL PROVISIONS OF THE BILL (HR 2617) P.L. 117-328: CONSOLIDATED APPROPRIATIONS ACT, 2023: PROVISIONS RELATED TO SECTIONS 3107, 3202, 3210, 3601-3607, 3629 S 350: NEWBORN SCREENING SAVES LIVES REAUTHORIZATION ACT OF 2021; ALL PROVISIONS OF THE BILL GENERAL DISCUSSIONS REGARDING FEDERAL DRUG ADMINISTRATION AND EUROPEAN MEDICINES AGENCY DRUG APPROVAL GENERAL DISCUSSIONS REGARDING ANTI-KICKBACK SAFE HARBOR FOR PATIENT TRAVEL COSTS GENERAL DISCUSSIONS REGARDING BUDGET RIDERS, ORPHAN DRUG ACT TAX CREDIT, AND VETERANS BENEFITS ADMINISTRATION
BENEFIT Act of 2021
Client: BIOMARIN PHARMACEUTICAL INC. · Firm: BIOMARIN PHARMACEUTICAL INC.
HR 4472: BETTER EMPOWERMENT NOW TO ENHANCE FRAMEWORK AND IMPROVE TREATMENTS (BENEFIT) ACT OF 2021; ALL PROVISIONS OF THE BILL HR 6000: CURES 2.0 ACT: PROVISIONS RELATED TO SECTIONS 203, 204, 303-309, 402, 403, 407 HR 6584: DIVERSE AND EQUITABLE PARTICIPATION IN CLINICAL TRIALS (DEPICT) ACT; ALL PROVISIONS OF THE BILL HR 6888: HELPING EXPERTS ACCELERATE RARE TREATMENTS ACT OF 2022; ALL PROVISIONS OF THE BILL HR 6963: ACCELERATED APPROVAL INTEGRITY ACT OF 2022; ALL PROVISIONS OF THE BILL HR 6996: ACCELERATING ACCESS FOR PATIENTS ACT OF 2022; ALL PROVISIONS OF THE BILL HR 7667: FOOD AND DRUG AMENDMENTS OF 2022; PROVISIONS RELATED TO TITLE V, SECTIONS 703 AND 804 S 373: BETTER EMPOWERMENT NOW TO ENHANCE FRAMEWORK AND IMPROVE TREATMENTS (BENEFIT) ACT OF 2021; ALL PROVISIONS OF THE BILL S 4071: HELPING EXPERTS ACCELERATE RARE TREATMENTS ACT OF 2022; ALL PROVISIONS OF THE BILL S 4348: FOOD AND DRUG ADMINISTRATION SAFETY AND LANDMARK ADVANCEMENTS ACT OF 2022 (FDASLA ACT); PROVISIONS RELATED TO SECTION 506 GENERAL DISCUSSIONS REGARDING ISSUES AFFECTING GENETIC BONE DISORDERS GENERAL DISCUSSIONS REGARDING HEMOPHILIA GENE THERAPY
BENEFIT Act of 2021
Client: BIOMARIN PHARMACEUTICAL INC. · Firm: BIOMARIN PHARMACEUTICAL INC.
HR 4472: BETTER EMPOWERMENT NOW TO ENHANCE FRAMEWORK AND IMPROVE TREATMENTS (BENEFIT) ACT OF 2021; ALL PROVISIONS OF THE BILL HR 6000: CURES 2.0 ACT: PROVISIONS RELATED TO SECTIONS 203, 204, 303-309, 402, 403, 407 HR 6584: DIVERSE AND EQUITABLE PARTICIPATION IN CLINICAL TRIALS (DEPICT) ACT; ALL PROVISIONS OF THE BILL HR 6888: HELPING EXPERTS ACCELERATE RARE TREATMENTS (HEART) ACT OF 2022; ALL PROVISIONS OF THE BILL HR 6963: ACCELERATED APPROVAL INTEGRITY ACT OF 2022; ALL PROVISIONS OF THE BILL HR 6996: ACCELERATING ACCESS FOR PATIENTS ACT OF 2022: ALL PROVISIONS OF THE BILL S 373: BETTER EMPOWERMENT NOW TO ENHANCE FRAMEWORK AND IMPROVE TREATMENTS (BENEFIT) ACT OF 2021; ALL PROVISIONS OF THE BILL GENERAL DISCUSSIONS REGARDING VALUE-BASED PAYMENT ARRANGEMENTS (VBA)
Newborn Screening Saves Lives Reauthorization Act of 2021
Client: BIOMARIN PHARMACEUTICAL INC. · Firm: BIOMARIN PHARMACEUTICAL INC.
HR 482: NEWBORN SCREENING SAVES LIVES REAUTHORIZATION ACT OF 2021; ALL PROVISIONS OF THE BILL HR 7667: FOOD AND DRUG AMENDMENTS OF 2022; PROVISIONS RELATED TO TITLE V, SECTIONS 703 AND 804 S 350: NEWBORN SCREENING SAVES LIVES REAUTHORIZATION ACT OF 2021; ALL PROVISIONS OF THE BILL S 4348: FOOD AND DRUG ADMINISTRATION SAFETY AND LANDMARK ADVANCEMENTS ACT OF 2022 (FDASLA ACT); PROVISIONS RELATED TO SECTION 506 GENERAL DISCUSSIONS REGARDING RARE DISEASES AND VETERANS BENEFITS ADMINISTRATIONS
Newborn Screening Saves Lives Reauthorization Act of 2021
Client: BIOMARIN PHARMACEUTICAL INC. · Firm: BIOMARIN PHARMACEUTICAL INC.
HR 482: NEWBORN SCREENING SAVES LIVES REAUTHORIZATION ACT OF 2021; ALL PROVISIONS OF THE BILL (HR 2617) P.L. 117-328: CONSOLIDATED APPROPRIATIONS ACT, 2023: PROVISIONS RELATED TO SECTIONS 3107, 3202, 3210, 3601-3607, 3629 S 350: NEWBORN SCREENING SAVES LIVES REAUTHORIZATION ACT OF 2021; ALL PROVISIONS OF THE BILL GENERAL DISCUSSIONS REGARDING FEDERAL DRUG ADMINISTRATION AND EUROPEAN MEDICINES AGENCY DRUG APPROVAL GENERAL DISCUSSIONS REGARDING ANTI-KICKBACK SAFE HARBOR FOR PATIENT TRAVEL COSTS GENERAL DISCUSSIONS REGARDING BUDGET RIDERS, ORPHAN DRUG ACT TAX CREDIT, AND VETERANS BENEFITS ADMINISTRATION
Inflation Reduction Act of 2022
Client: BIOMARIN PHARMACEUTICAL INC. · Firm: BIOMARIN PHARMACEUTICAL INC.
HR 5376: BUILD BACK BETTER ACT; PROVISIONS RELATED TO THE ORPHAN DRUG ACT
HR 4472: BETTER EMPOWERMENT NOW TO ENHANCE FRAMEWORK AND IMPROVE TREATMENTS (BENEFIT) ACT OF 2021; ALL PROVISIONS OF THE BILL HR 6000: CURES 2.0 ACT: PROVISIONS RELATED TO SECTIONS 203, 204, 303-309, 402, 403, 407 HR 6584: DIVERSE AND EQUITABLE PARTICIPATION IN CLINICAL TRIALS (DEPICT) ACT; ALL PROVISIONS OF THE BILL HR 6888: HELPING EXPERTS ACCELERATE RARE TREATMENTS (HEART) ACT OF 2022; ALL PROVISIONS OF THE BILL HR 6963: ACCELERATED APPROVAL INTEGRITY ACT OF 2022; ALL PROVISIONS OF THE BILL HR 6996: ACCELERATING ACCESS FOR PATIENTS ACT OF 2022: ALL PROVISIONS OF THE BILL S 373: BETTER EMPOWERMENT NOW TO ENHANCE FRAMEWORK AND IMPROVE TREATMENTS (BENEFIT) ACT OF 2021; ALL PROVISIONS OF THE BILL GENERAL DISCUSSIONS REGARDING VALUE-BASED PAYMENT ARRANGEMENTS (VBA)
HR 4472: BETTER EMPOWERMENT NOW TO ENHANCE FRAMEWORK AND IMPROVE TREATMENTS (BENEFIT) ACT OF 2021; ALL PROVISIONS OF THE BILL HR 6000: CURES 2.0 ACT: PROVISIONS RELATED TO SECTIONS 203, 204, 303-309, 402, 403, 407 HR 6584: DIVERSE AND EQUITABLE PARTICIPATION IN CLINICAL TRIALS (DEPICT) ACT; ALL PROVISIONS OF THE BILL HR 6888: HELPING EXPERTS ACCELERATE RARE TREATMENTS ACT OF 2022; ALL PROVISIONS OF THE BILL HR 6963: ACCELERATED APPROVAL INTEGRITY ACT OF 2022; ALL PROVISIONS OF THE BILL HR 6996: ACCELERATING ACCESS FOR PATIENTS ACT OF 2022; ALL PROVISIONS OF THE BILL HR 7667: FOOD AND DRUG AMENDMENTS OF 2022; PROVISIONS RELATED TO TITLE V, SECTIONS 703 AND 804 S 373: BETTER EMPOWERMENT NOW TO ENHANCE FRAMEWORK AND IMPROVE TREATMENTS (BENEFIT) ACT OF 2021; ALL PROVISIONS OF THE BILL S 4071: HELPING EXPERTS ACCELERATE RARE TREATMENTS ACT OF 2022; ALL PROVISIONS OF THE BILL S 4348: FOOD AND DRUG ADMINISTRATION SAFETY AND LANDMARK ADVANCEMENTS ACT OF 2022 (FDASLA ACT); PROVISIONS RELATED TO SECTION 506 GENERAL DISCUSSIONS REGARDING ISSUES AFFECTING GENETIC BONE DISORDERS GENERAL DISCUSSIONS REGARDING HEMOPHILIA GENE THERAPY
HR 4472: BETTER EMPOWERMENT NOW TO ENHANCE FRAMEWORK AND IMPROVE TREATMENTS (BENEFIT) ACT OF 2021; ALL PROVISIONS OF THE BILL HR 6000: CURES 2.0 ACT: PROVISIONS RELATED TO SECTIONS 203, 204, 303-309, 402, 403, 407 HR 6584: DIVERSE AND EQUITABLE PARTICIPATION IN CLINICAL TRIALS (DEPICT) ACT; ALL PROVISIONS OF THE BILL HR 6888: HELPING EXPERTS ACCELERATE RARE TREATMENTS ACT OF 2022; ALL PROVISIONS OF THE BILL HR 6963: ACCELERATED APPROVAL INTEGRITY ACT OF 2022; ALL PROVISIONS OF THE BILL HR 6996: ACCELERATING ACCESS FOR PATIENTS ACT OF 2022; ALL PROVISIONS OF THE BILL HR 7667: FOOD AND DRUG AMENDMENTS OF 2022; PROVISIONS RELATED TO TITLE V, SECTIONS 703 AND 804 S 373: BETTER EMPOWERMENT NOW TO ENHANCE FRAMEWORK AND IMPROVE TREATMENTS (BENEFIT) ACT OF 2021; ALL PROVISIONS OF THE BILL S 4071: HELPING EXPERTS ACCELERATE RARE TREATMENTS ACT OF 2022; ALL PROVISIONS OF THE BILL S 4348: FOOD AND DRUG ADMINISTRATION SAFETY AND LANDMARK ADVANCEMENTS ACT OF 2022 (FDASLA ACT); PROVISIONS RELATED TO SECTION 506 GENERAL DISCUSSIONS REGARDING ISSUES AFFECTING GENETIC BONE DISORDERS GENERAL DISCUSSIONS REGARDING HEMOPHILIA GENE THERAPY
HR 4472: BETTER EMPOWERMENT NOW TO ENHANCE FRAMEWORK AND IMPROVE TREATMENTS (BENEFIT) ACT OF 2021; ALL PROVISIONS OF THE BILL HR 6000: CURES 2.0 ACT: PROVISIONS RELATED TO SECTIONS 203, 204, 303-309, 402, 403, 407 HR 6584: DIVERSE AND EQUITABLE PARTICIPATION IN CLINICAL TRIALS (DEPICT) ACT; ALL PROVISIONS OF THE BILL HR 6888: HELPING EXPERTS ACCELERATE RARE TREATMENTS (HEART) ACT OF 2022; ALL PROVISIONS OF THE BILL HR 6963: ACCELERATED APPROVAL INTEGRITY ACT OF 2022; ALL PROVISIONS OF THE BILL HR 6996: ACCELERATING ACCESS FOR PATIENTS ACT OF 2022: ALL PROVISIONS OF THE BILL S 373: BETTER EMPOWERMENT NOW TO ENHANCE FRAMEWORK AND IMPROVE TREATMENTS (BENEFIT) ACT OF 2021; ALL PROVISIONS OF THE BILL GENERAL DISCUSSIONS REGARDING VALUE-BASED PAYMENT ARRANGEMENTS (VBA)
Helping Experts Accelerate Rare Treatments Act of 2022
Client: BIOMARIN PHARMACEUTICAL INC. · Firm: BIOMARIN PHARMACEUTICAL INC.
HR 4472: BETTER EMPOWERMENT NOW TO ENHANCE FRAMEWORK AND IMPROVE TREATMENTS (BENEFIT) ACT OF 2021; ALL PROVISIONS OF THE BILL HR 6000: CURES 2.0 ACT: PROVISIONS RELATED TO SECTIONS 203, 204, 303-309, 402, 403, 407 HR 6584: DIVERSE AND EQUITABLE PARTICIPATION IN CLINICAL TRIALS (DEPICT) ACT; ALL PROVISIONS OF THE BILL HR 6888: HELPING EXPERTS ACCELERATE RARE TREATMENTS (HEART) ACT OF 2022; ALL PROVISIONS OF THE BILL HR 6963: ACCELERATED APPROVAL INTEGRITY ACT OF 2022; ALL PROVISIONS OF THE BILL HR 6996: ACCELERATING ACCESS FOR PATIENTS ACT OF 2022: ALL PROVISIONS OF THE BILL S 373: BETTER EMPOWERMENT NOW TO ENHANCE FRAMEWORK AND IMPROVE TREATMENTS (BENEFIT) ACT OF 2021; ALL PROVISIONS OF THE BILL GENERAL DISCUSSIONS REGARDING VALUE-BASED PAYMENT ARRANGEMENTS (VBA)
Helping Experts Accelerate Rare Treatments Act of 2022
Client: BIOMARIN PHARMACEUTICAL INC. · Firm: BIOMARIN PHARMACEUTICAL INC.
HR 4472: BETTER EMPOWERMENT NOW TO ENHANCE FRAMEWORK AND IMPROVE TREATMENTS (BENEFIT) ACT OF 2021; ALL PROVISIONS OF THE BILL HR 6000: CURES 2.0 ACT: PROVISIONS RELATED TO SECTIONS 203, 204, 303-309, 402, 403, 407 HR 6584: DIVERSE AND EQUITABLE PARTICIPATION IN CLINICAL TRIALS (DEPICT) ACT; ALL PROVISIONS OF THE BILL HR 6888: HELPING EXPERTS ACCELERATE RARE TREATMENTS ACT OF 2022; ALL PROVISIONS OF THE BILL HR 6963: ACCELERATED APPROVAL INTEGRITY ACT OF 2022; ALL PROVISIONS OF THE BILL HR 6996: ACCELERATING ACCESS FOR PATIENTS ACT OF 2022; ALL PROVISIONS OF THE BILL HR 7667: FOOD AND DRUG AMENDMENTS OF 2022; PROVISIONS RELATED TO TITLE V, SECTIONS 703 AND 804 S 373: BETTER EMPOWERMENT NOW TO ENHANCE FRAMEWORK AND IMPROVE TREATMENTS (BENEFIT) ACT OF 2021; ALL PROVISIONS OF THE BILL S 4071: HELPING EXPERTS ACCELERATE RARE TREATMENTS ACT OF 2022; ALL PROVISIONS OF THE BILL S 4348: FOOD AND DRUG ADMINISTRATION SAFETY AND LANDMARK ADVANCEMENTS ACT OF 2022 (FDASLA ACT); PROVISIONS RELATED TO SECTION 506 GENERAL DISCUSSIONS REGARDING ISSUES AFFECTING GENETIC BONE DISORDERS GENERAL DISCUSSIONS REGARDING HEMOPHILIA GENE THERAPY
Accelerated Approval Integrity Act of 2022
Client: BIOMARIN PHARMACEUTICAL INC. · Firm: BIOMARIN PHARMACEUTICAL INC.
HR 4472: BETTER EMPOWERMENT NOW TO ENHANCE FRAMEWORK AND IMPROVE TREATMENTS (BENEFIT) ACT OF 2021; ALL PROVISIONS OF THE BILL HR 6000: CURES 2.0 ACT: PROVISIONS RELATED TO SECTIONS 203, 204, 303-309, 402, 403, 407 HR 6584: DIVERSE AND EQUITABLE PARTICIPATION IN CLINICAL TRIALS (DEPICT) ACT; ALL PROVISIONS OF THE BILL HR 6888: HELPING EXPERTS ACCELERATE RARE TREATMENTS ACT OF 2022; ALL PROVISIONS OF THE BILL HR 6963: ACCELERATED APPROVAL INTEGRITY ACT OF 2022; ALL PROVISIONS OF THE BILL HR 6996: ACCELERATING ACCESS FOR PATIENTS ACT OF 2022; ALL PROVISIONS OF THE BILL HR 7667: FOOD AND DRUG AMENDMENTS OF 2022; PROVISIONS RELATED TO TITLE V, SECTIONS 703 AND 804 S 373: BETTER EMPOWERMENT NOW TO ENHANCE FRAMEWORK AND IMPROVE TREATMENTS (BENEFIT) ACT OF 2021; ALL PROVISIONS OF THE BILL S 4071: HELPING EXPERTS ACCELERATE RARE TREATMENTS ACT OF 2022; ALL PROVISIONS OF THE BILL S 4348: FOOD AND DRUG ADMINISTRATION SAFETY AND LANDMARK ADVANCEMENTS ACT OF 2022 (FDASLA ACT); PROVISIONS RELATED TO SECTION 506 GENERAL DISCUSSIONS REGARDING ISSUES AFFECTING GENETIC BONE DISORDERS GENERAL DISCUSSIONS REGARDING HEMOPHILIA GENE THERAPY
Accelerated Approval Integrity Act of 2022
Client: BIOMARIN PHARMACEUTICAL INC. · Firm: BIOMARIN PHARMACEUTICAL INC.
HR 4472: BETTER EMPOWERMENT NOW TO ENHANCE FRAMEWORK AND IMPROVE TREATMENTS (BENEFIT) ACT OF 2021; ALL PROVISIONS OF THE BILL HR 6000: CURES 2.0 ACT: PROVISIONS RELATED TO SECTIONS 203, 204, 303-309, 402, 403, 407 HR 6584: DIVERSE AND EQUITABLE PARTICIPATION IN CLINICAL TRIALS (DEPICT) ACT; ALL PROVISIONS OF THE BILL HR 6888: HELPING EXPERTS ACCELERATE RARE TREATMENTS (HEART) ACT OF 2022; ALL PROVISIONS OF THE BILL HR 6963: ACCELERATED APPROVAL INTEGRITY ACT OF 2022; ALL PROVISIONS OF THE BILL HR 6996: ACCELERATING ACCESS FOR PATIENTS ACT OF 2022: ALL PROVISIONS OF THE BILL S 373: BETTER EMPOWERMENT NOW TO ENHANCE FRAMEWORK AND IMPROVE TREATMENTS (BENEFIT) ACT OF 2021; ALL PROVISIONS OF THE BILL GENERAL DISCUSSIONS REGARDING VALUE-BASED PAYMENT ARRANGEMENTS (VBA)
Accelerating Access for Patients Act of 2022
Client: BIOMARIN PHARMACEUTICAL INC. · Firm: BIOMARIN PHARMACEUTICAL INC.
HR 4472: BETTER EMPOWERMENT NOW TO ENHANCE FRAMEWORK AND IMPROVE TREATMENTS (BENEFIT) ACT OF 2021; ALL PROVISIONS OF THE BILL HR 6000: CURES 2.0 ACT: PROVISIONS RELATED TO SECTIONS 203, 204, 303-309, 402, 403, 407 HR 6584: DIVERSE AND EQUITABLE PARTICIPATION IN CLINICAL TRIALS (DEPICT) ACT; ALL PROVISIONS OF THE BILL HR 6888: HELPING EXPERTS ACCELERATE RARE TREATMENTS (HEART) ACT OF 2022; ALL PROVISIONS OF THE BILL HR 6963: ACCELERATED APPROVAL INTEGRITY ACT OF 2022; ALL PROVISIONS OF THE BILL HR 6996: ACCELERATING ACCESS FOR PATIENTS ACT OF 2022: ALL PROVISIONS OF THE BILL S 373: BETTER EMPOWERMENT NOW TO ENHANCE FRAMEWORK AND IMPROVE TREATMENTS (BENEFIT) ACT OF 2021; ALL PROVISIONS OF THE BILL GENERAL DISCUSSIONS REGARDING VALUE-BASED PAYMENT ARRANGEMENTS (VBA)
Accelerating Access for Patients Act of 2022
Client: BIOMARIN PHARMACEUTICAL INC. · Firm: BIOMARIN PHARMACEUTICAL INC.
HR 4472: BETTER EMPOWERMENT NOW TO ENHANCE FRAMEWORK AND IMPROVE TREATMENTS (BENEFIT) ACT OF 2021; ALL PROVISIONS OF THE BILL HR 6000: CURES 2.0 ACT: PROVISIONS RELATED TO SECTIONS 203, 204, 303-309, 402, 403, 407 HR 6584: DIVERSE AND EQUITABLE PARTICIPATION IN CLINICAL TRIALS (DEPICT) ACT; ALL PROVISIONS OF THE BILL HR 6888: HELPING EXPERTS ACCELERATE RARE TREATMENTS ACT OF 2022; ALL PROVISIONS OF THE BILL HR 6963: ACCELERATED APPROVAL INTEGRITY ACT OF 2022; ALL PROVISIONS OF THE BILL HR 6996: ACCELERATING ACCESS FOR PATIENTS ACT OF 2022; ALL PROVISIONS OF THE BILL HR 7667: FOOD AND DRUG AMENDMENTS OF 2022; PROVISIONS RELATED TO TITLE V, SECTIONS 703 AND 804 S 373: BETTER EMPOWERMENT NOW TO ENHANCE FRAMEWORK AND IMPROVE TREATMENTS (BENEFIT) ACT OF 2021; ALL PROVISIONS OF THE BILL S 4071: HELPING EXPERTS ACCELERATE RARE TREATMENTS ACT OF 2022; ALL PROVISIONS OF THE BILL S 4348: FOOD AND DRUG ADMINISTRATION SAFETY AND LANDMARK ADVANCEMENTS ACT OF 2022 (FDASLA ACT); PROVISIONS RELATED TO SECTION 506 GENERAL DISCUSSIONS REGARDING ISSUES AFFECTING GENETIC BONE DISORDERS GENERAL DISCUSSIONS REGARDING HEMOPHILIA GENE THERAPY
Food and Drug Amendments of 2022
Client: BIOMARIN PHARMACEUTICAL INC. · Firm: BIOMARIN PHARMACEUTICAL INC.
HR 4472: BETTER EMPOWERMENT NOW TO ENHANCE FRAMEWORK AND IMPROVE TREATMENTS (BENEFIT) ACT OF 2021; ALL PROVISIONS OF THE BILL HR 6000: CURES 2.0 ACT: PROVISIONS RELATED TO SECTIONS 203, 204, 303-309, 402, 403, 407 HR 6584: DIVERSE AND EQUITABLE PARTICIPATION IN CLINICAL TRIALS (DEPICT) ACT; ALL PROVISIONS OF THE BILL HR 6888: HELPING EXPERTS ACCELERATE RARE TREATMENTS ACT OF 2022; ALL PROVISIONS OF THE BILL HR 6963: ACCELERATED APPROVAL INTEGRITY ACT OF 2022; ALL PROVISIONS OF THE BILL HR 6996: ACCELERATING ACCESS FOR PATIENTS ACT OF 2022; ALL PROVISIONS OF THE BILL HR 7667: FOOD AND DRUG AMENDMENTS OF 2022; PROVISIONS RELATED TO TITLE V, SECTIONS 703 AND 804 S 373: BETTER EMPOWERMENT NOW TO ENHANCE FRAMEWORK AND IMPROVE TREATMENTS (BENEFIT) ACT OF 2021; ALL PROVISIONS OF THE BILL S 4071: HELPING EXPERTS ACCELERATE RARE TREATMENTS ACT OF 2022; ALL PROVISIONS OF THE BILL S 4348: FOOD AND DRUG ADMINISTRATION SAFETY AND LANDMARK ADVANCEMENTS ACT OF 2022 (FDASLA ACT); PROVISIONS RELATED TO SECTION 506 GENERAL DISCUSSIONS REGARDING ISSUES AFFECTING GENETIC BONE DISORDERS GENERAL DISCUSSIONS REGARDING HEMOPHILIA GENE THERAPY
Food and Drug Amendments of 2022
Client: BIOMARIN PHARMACEUTICAL INC. · Firm: BIOMARIN PHARMACEUTICAL INC.
HR 482: NEWBORN SCREENING SAVES LIVES REAUTHORIZATION ACT OF 2021; ALL PROVISIONS OF THE BILL HR 7667: FOOD AND DRUG AMENDMENTS OF 2022; PROVISIONS RELATED TO TITLE V, SECTIONS 703 AND 804 S 350: NEWBORN SCREENING SAVES LIVES REAUTHORIZATION ACT OF 2021; ALL PROVISIONS OF THE BILL S 4348: FOOD AND DRUG ADMINISTRATION SAFETY AND LANDMARK ADVANCEMENTS ACT OF 2022 (FDASLA ACT); PROVISIONS RELATED TO SECTION 506 GENERAL DISCUSSIONS REGARDING RARE DISEASES AND VETERANS BENEFITS ADMINISTRATIONS
Newborn Screening Saves Lives Reauthorization Act of 2021
Client: BIOMARIN PHARMACEUTICAL INC. · Firm: BIOMARIN PHARMACEUTICAL INC.
HR 482: NEWBORN SCREENING SAVES LIVES REAUTHORIZATION ACT OF 2021; ALL PROVISIONS OF THE BILL (HR 2617) P.L. 117-328: CONSOLIDATED APPROPRIATIONS ACT, 2023: PROVISIONS RELATED TO SECTIONS 3107, 3202, 3210, 3601-3607, 3629 S 350: NEWBORN SCREENING SAVES LIVES REAUTHORIZATION ACT OF 2021; ALL PROVISIONS OF THE BILL GENERAL DISCUSSIONS REGARDING FEDERAL DRUG ADMINISTRATION AND EUROPEAN MEDICINES AGENCY DRUG APPROVAL GENERAL DISCUSSIONS REGARDING ANTI-KICKBACK SAFE HARBOR FOR PATIENT TRAVEL COSTS GENERAL DISCUSSIONS REGARDING BUDGET RIDERS, ORPHAN DRUG ACT TAX CREDIT, AND VETERANS BENEFITS ADMINISTRATION
Newborn Screening Saves Lives Reauthorization Act of 2021
Client: BIOMARIN PHARMACEUTICAL INC. · Firm: BIOMARIN PHARMACEUTICAL INC.
HR 482: NEWBORN SCREENING SAVES LIVES REAUTHORIZATION ACT OF 2021; ALL PROVISIONS OF THE BILL HR 7667: FOOD AND DRUG AMENDMENTS OF 2022; PROVISIONS RELATED TO TITLE V, SECTIONS 703 AND 804 S 350: NEWBORN SCREENING SAVES LIVES REAUTHORIZATION ACT OF 2021; ALL PROVISIONS OF THE BILL S 4348: FOOD AND DRUG ADMINISTRATION SAFETY AND LANDMARK ADVANCEMENTS ACT OF 2022 (FDASLA ACT); PROVISIONS RELATED TO SECTION 506 GENERAL DISCUSSIONS REGARDING RARE DISEASES AND VETERANS BENEFITS ADMINISTRATIONS
HR 4472: BETTER EMPOWERMENT NOW TO ENHANCE FRAMEWORK AND IMPROVE TREATMENTS (BENEFIT) ACT OF 2021; ALL PROVISIONS OF THE BILL HR 6000: CURES 2.0 ACT: PROVISIONS RELATED TO SECTIONS 203, 204, 303-309, 402, 403, 407 HR 6584: DIVERSE AND EQUITABLE PARTICIPATION IN CLINICAL TRIALS (DEPICT) ACT; ALL PROVISIONS OF THE BILL HR 6888: HELPING EXPERTS ACCELERATE RARE TREATMENTS ACT OF 2022; ALL PROVISIONS OF THE BILL HR 6963: ACCELERATED APPROVAL INTEGRITY ACT OF 2022; ALL PROVISIONS OF THE BILL HR 6996: ACCELERATING ACCESS FOR PATIENTS ACT OF 2022; ALL PROVISIONS OF THE BILL HR 7667: FOOD AND DRUG AMENDMENTS OF 2022; PROVISIONS RELATED TO TITLE V, SECTIONS 703 AND 804 S 373: BETTER EMPOWERMENT NOW TO ENHANCE FRAMEWORK AND IMPROVE TREATMENTS (BENEFIT) ACT OF 2021; ALL PROVISIONS OF THE BILL S 4071: HELPING EXPERTS ACCELERATE RARE TREATMENTS ACT OF 2022; ALL PROVISIONS OF THE BILL S 4348: FOOD AND DRUG ADMINISTRATION SAFETY AND LANDMARK ADVANCEMENTS ACT OF 2022 (FDASLA ACT); PROVISIONS RELATED TO SECTION 506 GENERAL DISCUSSIONS REGARDING ISSUES AFFECTING GENETIC BONE DISORDERS GENERAL DISCUSSIONS REGARDING HEMOPHILIA GENE THERAPY
HR 4472: BETTER EMPOWERMENT NOW TO ENHANCE FRAMEWORK AND IMPROVE TREATMENTS (BENEFIT) ACT OF 2021; ALL PROVISIONS OF THE BILL HR 6000: CURES 2.0 ACT: PROVISIONS RELATED TO SECTIONS 203, 204, 303-309, 402, 403, 407 HR 6584: DIVERSE AND EQUITABLE PARTICIPATION IN CLINICAL TRIALS (DEPICT) ACT; ALL PROVISIONS OF THE BILL HR 6888: HELPING EXPERTS ACCELERATE RARE TREATMENTS (HEART) ACT OF 2022; ALL PROVISIONS OF THE BILL HR 6963: ACCELERATED APPROVAL INTEGRITY ACT OF 2022; ALL PROVISIONS OF THE BILL HR 6996: ACCELERATING ACCESS FOR PATIENTS ACT OF 2022: ALL PROVISIONS OF THE BILL S 373: BETTER EMPOWERMENT NOW TO ENHANCE FRAMEWORK AND IMPROVE TREATMENTS (BENEFIT) ACT OF 2021; ALL PROVISIONS OF THE BILL GENERAL DISCUSSIONS REGARDING VALUE-BASED PAYMENT ARRANGEMENTS (VBA)
Helping Experts Accelerate Rare Treatments Act of 2022
Client: BIOMARIN PHARMACEUTICAL INC. · Firm: BIOMARIN PHARMACEUTICAL INC.
HR 4472: BETTER EMPOWERMENT NOW TO ENHANCE FRAMEWORK AND IMPROVE TREATMENTS (BENEFIT) ACT OF 2021; ALL PROVISIONS OF THE BILL HR 6000: CURES 2.0 ACT: PROVISIONS RELATED TO SECTIONS 203, 204, 303-309, 402, 403, 407 HR 6584: DIVERSE AND EQUITABLE PARTICIPATION IN CLINICAL TRIALS (DEPICT) ACT; ALL PROVISIONS OF THE BILL HR 6888: HELPING EXPERTS ACCELERATE RARE TREATMENTS ACT OF 2022; ALL PROVISIONS OF THE BILL HR 6963: ACCELERATED APPROVAL INTEGRITY ACT OF 2022; ALL PROVISIONS OF THE BILL HR 6996: ACCELERATING ACCESS FOR PATIENTS ACT OF 2022; ALL PROVISIONS OF THE BILL HR 7667: FOOD AND DRUG AMENDMENTS OF 2022; PROVISIONS RELATED TO TITLE V, SECTIONS 703 AND 804 S 373: BETTER EMPOWERMENT NOW TO ENHANCE FRAMEWORK AND IMPROVE TREATMENTS (BENEFIT) ACT OF 2021; ALL PROVISIONS OF THE BILL S 4071: HELPING EXPERTS ACCELERATE RARE TREATMENTS ACT OF 2022; ALL PROVISIONS OF THE BILL S 4348: FOOD AND DRUG ADMINISTRATION SAFETY AND LANDMARK ADVANCEMENTS ACT OF 2022 (FDASLA ACT); PROVISIONS RELATED TO SECTION 506 GENERAL DISCUSSIONS REGARDING ISSUES AFFECTING GENETIC BONE DISORDERS GENERAL DISCUSSIONS REGARDING HEMOPHILIA GENE THERAPY
HR 482: NEWBORN SCREENING SAVES LIVES REAUTHORIZATION ACT OF 2021; ALL PROVISIONS OF THE BILL HR 7667: FOOD AND DRUG AMENDMENTS OF 2022; PROVISIONS RELATED TO TITLE V, SECTIONS 703 AND 804 S 350: NEWBORN SCREENING SAVES LIVES REAUTHORIZATION ACT OF 2021; ALL PROVISIONS OF THE BILL S 4348: FOOD AND DRUG ADMINISTRATION SAFETY AND LANDMARK ADVANCEMENTS ACT OF 2022 (FDASLA ACT); PROVISIONS RELATED TO SECTION 506 GENERAL DISCUSSIONS REGARDING RARE DISEASES AND VETERANS BENEFITS ADMINISTRATIONS
HR 4472: BETTER EMPOWERMENT NOW TO ENHANCE FRAMEWORK AND IMPROVE TREATMENTS (BENEFIT) ACT OF 2021; ALL PROVISIONS OF THE BILL HR 6000: CURES 2.0 ACT: PROVISIONS RELATED TO SECTIONS 203, 204, 303-309, 402, 403, 407 HR 6584: DIVERSE AND EQUITABLE PARTICIPATION IN CLINICAL TRIALS (DEPICT) ACT; ALL PROVISIONS OF THE BILL HR 6888: HELPING EXPERTS ACCELERATE RARE TREATMENTS ACT OF 2022; ALL PROVISIONS OF THE BILL HR 6963: ACCELERATED APPROVAL INTEGRITY ACT OF 2022; ALL PROVISIONS OF THE BILL HR 6996: ACCELERATING ACCESS FOR PATIENTS ACT OF 2022; ALL PROVISIONS OF THE BILL HR 7667: FOOD AND DRUG AMENDMENTS OF 2022; PROVISIONS RELATED TO TITLE V, SECTIONS 703 AND 804 S 373: BETTER EMPOWERMENT NOW TO ENHANCE FRAMEWORK AND IMPROVE TREATMENTS (BENEFIT) ACT OF 2021; ALL PROVISIONS OF THE BILL S 4071: HELPING EXPERTS ACCELERATE RARE TREATMENTS ACT OF 2022; ALL PROVISIONS OF THE BILL S 4348: FOOD AND DRUG ADMINISTRATION SAFETY AND LANDMARK ADVANCEMENTS ACT OF 2022 (FDASLA ACT); PROVISIONS RELATED TO SECTION 506 GENERAL DISCUSSIONS REGARDING ISSUES AFFECTING GENETIC BONE DISORDERS GENERAL DISCUSSIONS REGARDING HEMOPHILIA GENE THERAPY
Helping Experts Accelerate Rare Treatments Act of 2021
Client: BIOMARIN PHARMACEUTICAL INC. · Firm: BIOMARIN PHARMACEUTICAL INC.
HR 482: NEWBORN SCREENING SAVES LIVES REAUTHORIZATION ACT OF 2021; ALL PROVISIONS OF THE BILL HR 1184: HELPING EXPERTS ACCELERATE RARE TREATMENTS (HEART) ACT OF 2021; ALL PROVISIONS OF THE BILL S 350: NEWBORN SCREENING SAVES LIVES REAUTHORIZATION ACT OF 2021; ALL PROVISIONS OF THE BILL S 373: BENEFIT ACT OF 2021; PROVISIONS RELATED TO RARE DISEASES S 2164: LOWER COSTS, MORE CURES ACT OF 2021; PROVISIONS RELATED TO VALUE BASED ARRANGEMENTS GENERAL DISCUSSIONS RELATED TO THE 21ST CENTURY CURES ACT 2.0 GENERAL DISCUSSIONS RELATED TO THE ORPHAN DRUG ACT
HR 2623: CAMERON'S LAW; ALL PROVISIONS OF THE BILL HR 5376: BUILD BACK BETTER ACT; PROVISIONS RELATED TO SECTION 138141 GENERAL DISCUSSIONS REGARDING THE ORPHAN DRUG ACT
HR 2623: CAMERON'S LAW; ALL PROVISIONS OF THE BILL HR 5376: BUILD BACK BETTER ACT; PROVISIONS RELATED TO SECTIONS 138121, 138126, 138127, 138141, 139001, 139101, 139102, 139201, AND THE ORPHAN DRUG ACT TAX CREDIT
Newborn Screening Saves Lives Reauthorization Act of 2021
Client: BIOMARIN PHARMACEUTICAL INC. · Firm: BIOMARIN PHARMACEUTICAL INC.
HR 482: NEWBORN SCREENING SAVES LIVES REAUTHORIZATION ACT OF 2021; ALL PROVISIONS OF THE BILL S 350: NEWBORN SCREENING SAVES LIVES REAUTHORIZATION ACT OF 2021; ALL PROVISIONS OF THE BILL GENERAL DISCUSSIONS RELATED TO THE 21ST CENTURY CURES ACT 2.0 GENERAL DISCUSSIONS RELATED TO THE OUTCOME-BASED ARRANGEMENTS
Newborn Screening Saves Lives Reauthorization Act of 2021
Client: BIOMARIN PHARMACEUTICAL INC. · Firm: BIOMARIN PHARMACEUTICAL INC.
HR 482: NEWBORN SCREENING SAVES LIVES REAUTHORIZATION ACT OF 2021; ALL PROVISIONS OF THE BILL HR 1184: HELPING EXPERTS ACCELERATE RARE TREATMENTS (HEART) ACT OF 2021; ALL PROVISIONS OF THE BILL S 350: NEWBORN SCREENING SAVES LIVES REAUTHORIZATION ACT OF 2021; ALL PROVISIONS OF THE BILL S 373: BENEFIT ACT OF 2021; PROVISIONS RELATED TO RARE DISEASES S 2164: LOWER COSTS, MORE CURES ACT OF 2021; PROVISIONS RELATED TO VALUE BASED ARRANGEMENTS GENERAL DISCUSSIONS RELATED TO THE 21ST CENTURY CURES ACT 2.0 GENERAL DISCUSSIONS RELATED TO THE ORPHAN DRUG ACT
Inflation Reduction Act of 2022
Client: BIOMARIN PHARMACEUTICAL INC. · Firm: BIOMARIN PHARMACEUTICAL INC.
HR 2623: CAMERON'S LAW; ALL PROVISIONS OF THE BILL HR 5376: BUILD BACK BETTER ACT; PROVISIONS RELATED TO SECTION 138141 GENERAL DISCUSSIONS REGARDING THE ORPHAN DRUG ACT
Inflation Reduction Act of 2022
Client: BIOMARIN PHARMACEUTICAL INC. · Firm: BIOMARIN PHARMACEUTICAL INC.
HR 2623: CAMERON'S LAW; ALL PROVISIONS OF THE BILL HR 5376: BUILD BACK BETTER ACT; PROVISIONS RELATED TO SECTIONS 138121, 138126, 138127, 138141, 139001, 139101, 139102, 139201, AND THE ORPHAN DRUG ACT TAX CREDIT
HR 842: NEWBORN SCREENING SAVES LIVES REAUTHORIZATION ACT OF 2021; ALL PROVISIONS OF THE BILL HR 6000: CURES 2.0 ACT: PROVISIONS RELATED TO SECTIONS 203, 204, 303-309, 402, 403, 407, AND RARE DISEASES S 350: NEWBORN SCREENING SAVES LIVES REAUTHORIZATION ACT OF 2021; ALL PROVISIONS OF THE BILL GENERAL DISCUSSIONS REGARDING THE 21ST CENTURY CURES ACT 2.0
Protecting the Right to Organize Act of 2021
Client: BIOMARIN PHARMACEUTICAL INC. · Firm: BIOMARIN PHARMACEUTICAL INC.
HR 842: NEWBORN SCREENING SAVES LIVES REAUTHORIZATION ACT OF 2021; ALL PROVISIONS OF THE BILL HR 6000: CURES 2.0 ACT: PROVISIONS RELATED TO SECTIONS 203, 204, 303-309, 402, 403, 407, AND RARE DISEASES S 350: NEWBORN SCREENING SAVES LIVES REAUTHORIZATION ACT OF 2021; ALL PROVISIONS OF THE BILL GENERAL DISCUSSIONS REGARDING THE 21ST CENTURY CURES ACT 2.0
Lower Costs, More Cures Act of 2021
Client: BIOMARIN PHARMACEUTICAL INC. · Firm: BIOMARIN PHARMACEUTICAL INC.
HR 482: NEWBORN SCREENING SAVES LIVES REAUTHORIZATION ACT OF 2021; ALL PROVISIONS OF THE BILL HR 1184: HELPING EXPERTS ACCELERATE RARE TREATMENTS (HEART) ACT OF 2021; ALL PROVISIONS OF THE BILL S 350: NEWBORN SCREENING SAVES LIVES REAUTHORIZATION ACT OF 2021; ALL PROVISIONS OF THE BILL S 373: BENEFIT ACT OF 2021; PROVISIONS RELATED TO RARE DISEASES S 2164: LOWER COSTS, MORE CURES ACT OF 2021; PROVISIONS RELATED TO VALUE BASED ARRANGEMENTS GENERAL DISCUSSIONS RELATED TO THE 21ST CENTURY CURES ACT 2.0 GENERAL DISCUSSIONS RELATED TO THE ORPHAN DRUG ACT
Newborn Screening Saves Lives Reauthorization Act of 2021
Client: BIOMARIN PHARMACEUTICAL INC. · Firm: BIOMARIN PHARMACEUTICAL INC.
HR 842: NEWBORN SCREENING SAVES LIVES REAUTHORIZATION ACT OF 2021; ALL PROVISIONS OF THE BILL HR 6000: CURES 2.0 ACT: PROVISIONS RELATED TO SECTIONS 203, 204, 303-309, 402, 403, 407, AND RARE DISEASES S 350: NEWBORN SCREENING SAVES LIVES REAUTHORIZATION ACT OF 2021; ALL PROVISIONS OF THE BILL GENERAL DISCUSSIONS REGARDING THE 21ST CENTURY CURES ACT 2.0
Newborn Screening Saves Lives Reauthorization Act of 2021
Client: BIOMARIN PHARMACEUTICAL INC. · Firm: BIOMARIN PHARMACEUTICAL INC.
HR 482: NEWBORN SCREENING SAVES LIVES REAUTHORIZATION ACT OF 2021; ALL PROVISIONS OF THE BILL S 350: NEWBORN SCREENING SAVES LIVES REAUTHORIZATION ACT OF 2021; ALL PROVISIONS OF THE BILL GENERAL DISCUSSIONS RELATED TO THE 21ST CENTURY CURES ACT 2.0 GENERAL DISCUSSIONS RELATED TO THE OUTCOME-BASED ARRANGEMENTS
Newborn Screening Saves Lives Reauthorization Act of 2021
Client: BIOMARIN PHARMACEUTICAL INC. · Firm: BIOMARIN PHARMACEUTICAL INC.
HR 482: NEWBORN SCREENING SAVES LIVES REAUTHORIZATION ACT OF 2021; ALL PROVISIONS OF THE BILL HR 1184: HELPING EXPERTS ACCELERATE RARE TREATMENTS (HEART) ACT OF 2021; ALL PROVISIONS OF THE BILL S 350: NEWBORN SCREENING SAVES LIVES REAUTHORIZATION ACT OF 2021; ALL PROVISIONS OF THE BILL S 373: BENEFIT ACT OF 2021; PROVISIONS RELATED TO RARE DISEASES S 2164: LOWER COSTS, MORE CURES ACT OF 2021; PROVISIONS RELATED TO VALUE BASED ARRANGEMENTS GENERAL DISCUSSIONS RELATED TO THE 21ST CENTURY CURES ACT 2.0 GENERAL DISCUSSIONS RELATED TO THE ORPHAN DRUG ACT
HR 482: NEWBORN SCREENING SAVES LIVES REAUTHORIZATION ACT OF 2021; ALL PROVISIONS OF THE BILL HR 1184: HELPING EXPERTS ACCELERATE RARE TREATMENTS (HEART) ACT OF 2021; ALL PROVISIONS OF THE BILL S 350: NEWBORN SCREENING SAVES LIVES REAUTHORIZATION ACT OF 2021; ALL PROVISIONS OF THE BILL S 373: BENEFIT ACT OF 2021; PROVISIONS RELATED TO RARE DISEASES S 2164: LOWER COSTS, MORE CURES ACT OF 2021; PROVISIONS RELATED TO VALUE BASED ARRANGEMENTS GENERAL DISCUSSIONS RELATED TO THE 21ST CENTURY CURES ACT 2.0 GENERAL DISCUSSIONS RELATED TO THE ORPHAN DRUG ACT
Newborn Screening Saves Lives Reauthorization Act of 2019
Client: BIOMARIN PHARMACEUTICAL INC. · Firm: BIOMARIN PHARMACEUTICAL INC.
H.R. 2507: NEWBORN SCREENING SAVES LIVES REAUTHORIZATION ACT OF 2019; ALL PROVISIONS OF THE BILL H.R. 6238: CAMERON'S LAW; ALL PROVISIONS OF THE BILL S 2158: NEWBORN SCREENING SAVES LIVES REAUTHORIZATION ACT OF 2019; ALL PROVISIONS OF THE BILL GENERAL DISCUSSIONS REGARDING PRESCRIPTION DRUG PRICING AND GENE THERAPY GENERAL DISCUSSIONS REGARDING ORPHAN DRUG ACT
Newborn Screening Saves Lives Reauthorization Act of 2019
Client: BIOMARIN PHARMACEUTICAL INC. · Firm: BIOMARIN PHARMACEUTICAL INC.
H.R. 2507: NEWBORN SCREENING SAVES LIVES REAUTHORIZATION ACT OF 2019; ALL PROVISIONS OF THE BILL H.R. 4439: CREATING HOPE REAUTHORIZATION ACT; ALL PROVISIONS OF THE BILL S 2158: NEWBORN SCREENING SAVES LIVES REAUTHORIZATION ACT OF 2019; ALL PROVISIONS OF THE BILL S 4010: CREATING HOPE REAUTHORIZATION ACT; ALL PROVISIONS OF THE BILL CONTROLLED SUBSTANCE UTILIZATION REVIEW AND EVALUATION SYSTEM 2.0: GENERAL DISCUSSIONS REGARDING INNOVATION GENERAL DISCUSSIONS REGARDING GENE THERAPY AND OFFICE OF BIOTECHNOLOGY ACTIVITIES GENERAL DISCUSSIONS REGARDING ORPHAN DRUG ACT
Newborn Screening Saves Lives Reauthorization Act of 2019
Client: BIOMARIN PHARMACEUTICAL INC. · Firm: BIOMARIN PHARMACEUTICAL INC.
H.R. 2507: NEWBORN SCREENING SAVES LIVES REAUTHORIZATION ACT OF 2019; ALL PROVISIONS OF THE BILL H.R. 4439: CREATING HOPE REAUTHORIZATION ACT; ALL PROVISIONS OF THE BILL H.R. 4712: FAIRNESS IN ORPHAN DRUG EXCLUSIVITY ACT; ALL PROVISIONS OF THE BILL H.R. 7567: HELPING EXPERTS ACCELERATE RARE TREATMENTS (HEARTS) ACT OF 2020; ALL PROVISIONS OF THE BILL H.R. 7647: TO PROVIDE FOR A COVID-19-RELATED DELAY REGARDING ANNUAL LIMITATION ON COST-SHARING FOR GROUP HEALTH PLANS AND INDIVIDUAL AND SMALL GROUP HEALTH INSURANCE COVERAGE; ALL PROVISIONS OF THE BILL S. 2158: NEWBORN SCREENING SAVES LIVES REAUTHORIZATION ACT OF 2019; ALL PROVISIONS OF THE BILL S. 4010: CREATING HOPE REAUTHORIZATION ACT; ALL PROVISIONS OF THE BILL GENERAL DISCUSSIONS REGARDING FOOD & DRUG ADMINISTRATION'S COMPLETE RESPONSE LETTER; BREAKTHROUGH THERAPY PROGRAM; HEALTH INNOVATION; NEWBORN SCREENING; VALUE BASED ARRANGEMENTS
For the relief of Maria Isabel Bueso Barrera, Alberto Bueso Mendoza, Karla Maria Barrera De Bueso, and Ana Lucia Bueso Barrera.
Client: BIOMARIN PHARMACEUTICAL INC. · Firm: BIOMARIN PHARMACEUTICAL INC.
H.R. 4225: FOR THE RELIEF OF MARIA ISABEL BUESO BARRERA, ALBERTO BUESO MENDOZA, KARLA MARIA BARRERA DE BUESO, AND ANA LUCIA BUESO BARRERA; ALL PROVISIONS OF THE BILL S. 2612: FOR THE RELIEF OF MARIA ISABEL BUESO BARRERA, ALBERTO BUESO MENDOZA, AND KARLA MARIA BARRERA DE BUESO; ALL PROVISIONS OF THE BILL
Creating Hope Reauthorization Act
Client: BIOMARIN PHARMACEUTICAL INC. · Firm: BIOMARIN PHARMACEUTICAL INC.
H.R. 4439: CREATING HOPE REAUTHORIZATION ACT; ALL PROVISIONS OF THE BILL S. 4010: CREATING HOPE REAUTHORIZATION ACT; ALL PROVISIONS OF THE BILL GENERAL DISCUSSIONS REGARDING HEALTH INNOVATION; VALUE BASED ARRANGEMENTS; FDA BREAKTHROUGH THERAPY DESIGNATION AND RESPONSE LETTER; 21ST CENTURY CURES ACT 2.0
Creating Hope Reauthorization Act
Client: BIOMARIN PHARMACEUTICAL INC. · Firm: BIOMARIN PHARMACEUTICAL INC.
H.R. 2507: NEWBORN SCREENING SAVES LIVES REAUTHORIZATION ACT OF 2019; ALL PROVISIONS OF THE BILL H.R. 4439: CREATING HOPE REAUTHORIZATION ACT; ALL PROVISIONS OF THE BILL H.R. 4712: FAIRNESS IN ORPHAN DRUG EXCLUSIVITY ACT; ALL PROVISIONS OF THE BILL H.R. 7567: HELPING EXPERTS ACCELERATE RARE TREATMENTS (HEARTS) ACT OF 2020; ALL PROVISIONS OF THE BILL H.R. 7647: TO PROVIDE FOR A COVID-19-RELATED DELAY REGARDING ANNUAL LIMITATION ON COST-SHARING FOR GROUP HEALTH PLANS AND INDIVIDUAL AND SMALL GROUP HEALTH INSURANCE COVERAGE; ALL PROVISIONS OF THE BILL S. 2158: NEWBORN SCREENING SAVES LIVES REAUTHORIZATION ACT OF 2019; ALL PROVISIONS OF THE BILL S. 4010: CREATING HOPE REAUTHORIZATION ACT; ALL PROVISIONS OF THE BILL GENERAL DISCUSSIONS REGARDING FOOD & DRUG ADMINISTRATION'S COMPLETE RESPONSE LETTER; BREAKTHROUGH THERAPY PROGRAM; HEALTH INNOVATION; NEWBORN SCREENING; VALUE BASED ARRANGEMENTS
Creating Hope Reauthorization Act
Client: BIOMARIN PHARMACEUTICAL INC. · Firm: BIOMARIN PHARMACEUTICAL INC.
H.R. 2507: NEWBORN SCREENING SAVES LIVES REAUTHORIZATION ACT OF 2019; ALL PROVISIONS OF THE BILL H.R. 4439: CREATING HOPE REAUTHORIZATION ACT; ALL PROVISIONS OF THE BILL S 2158: NEWBORN SCREENING SAVES LIVES REAUTHORIZATION ACT OF 2019; ALL PROVISIONS OF THE BILL S 4010: CREATING HOPE REAUTHORIZATION ACT; ALL PROVISIONS OF THE BILL CONTROLLED SUBSTANCE UTILIZATION REVIEW AND EVALUATION SYSTEM 2.0: GENERAL DISCUSSIONS REGARDING INNOVATION GENERAL DISCUSSIONS REGARDING GENE THERAPY AND OFFICE OF BIOTECHNOLOGY ACTIVITIES GENERAL DISCUSSIONS REGARDING ORPHAN DRUG ACT
Fairness in Orphan Drug Exclusivity Act
Client: BIOMARIN PHARMACEUTICAL INC. · Firm: BIOMARIN PHARMACEUTICAL INC.
H.R. 2507: NEWBORN SCREENING SAVES LIVES REAUTHORIZATION ACT OF 2019; ALL PROVISIONS OF THE BILL H.R. 4439: CREATING HOPE REAUTHORIZATION ACT; ALL PROVISIONS OF THE BILL H.R. 4712: FAIRNESS IN ORPHAN DRUG EXCLUSIVITY ACT; ALL PROVISIONS OF THE BILL H.R. 7567: HELPING EXPERTS ACCELERATE RARE TREATMENTS (HEARTS) ACT OF 2020; ALL PROVISIONS OF THE BILL H.R. 7647: TO PROVIDE FOR A COVID-19-RELATED DELAY REGARDING ANNUAL LIMITATION ON COST-SHARING FOR GROUP HEALTH PLANS AND INDIVIDUAL AND SMALL GROUP HEALTH INSURANCE COVERAGE; ALL PROVISIONS OF THE BILL S. 2158: NEWBORN SCREENING SAVES LIVES REAUTHORIZATION ACT OF 2019; ALL PROVISIONS OF THE BILL S. 4010: CREATING HOPE REAUTHORIZATION ACT; ALL PROVISIONS OF THE BILL GENERAL DISCUSSIONS REGARDING FOOD & DRUG ADMINISTRATION'S COMPLETE RESPONSE LETTER; BREAKTHROUGH THERAPY PROGRAM; HEALTH INNOVATION; NEWBORN SCREENING; VALUE BASED ARRANGEMENTS
H.R. 2507: NEWBORN SCREENING SAVES LIVES REAUTHORIZATION ACT OF 2019; ALL PROVISIONS OF THE BILL H.R. 6238: CAMERON'S LAW; ALL PROVISIONS OF THE BILL S 2158: NEWBORN SCREENING SAVES LIVES REAUTHORIZATION ACT OF 2019; ALL PROVISIONS OF THE BILL GENERAL DISCUSSIONS REGARDING PRESCRIPTION DRUG PRICING AND GENE THERAPY GENERAL DISCUSSIONS REGARDING ORPHAN DRUG ACT
Helping Experts Accelerate Rare Treatments Act of 2020
Client: BIOMARIN PHARMACEUTICAL INC. · Firm: BIOMARIN PHARMACEUTICAL INC.
H.R. 2507: NEWBORN SCREENING SAVES LIVES REAUTHORIZATION ACT OF 2019; ALL PROVISIONS OF THE BILL H.R. 4439: CREATING HOPE REAUTHORIZATION ACT; ALL PROVISIONS OF THE BILL H.R. 4712: FAIRNESS IN ORPHAN DRUG EXCLUSIVITY ACT; ALL PROVISIONS OF THE BILL H.R. 7567: HELPING EXPERTS ACCELERATE RARE TREATMENTS (HEARTS) ACT OF 2020; ALL PROVISIONS OF THE BILL H.R. 7647: TO PROVIDE FOR A COVID-19-RELATED DELAY REGARDING ANNUAL LIMITATION ON COST-SHARING FOR GROUP HEALTH PLANS AND INDIVIDUAL AND SMALL GROUP HEALTH INSURANCE COVERAGE; ALL PROVISIONS OF THE BILL S. 2158: NEWBORN SCREENING SAVES LIVES REAUTHORIZATION ACT OF 2019; ALL PROVISIONS OF THE BILL S. 4010: CREATING HOPE REAUTHORIZATION ACT; ALL PROVISIONS OF THE BILL GENERAL DISCUSSIONS REGARDING FOOD & DRUG ADMINISTRATION'S COMPLETE RESPONSE LETTER; BREAKTHROUGH THERAPY PROGRAM; HEALTH INNOVATION; NEWBORN SCREENING; VALUE BASED ARRANGEMENTS
To provide for a COVID-19-related delay regarding annual limitation on cost-sharing for group health plans and individual and small group health insurance coverage.
Client: BIOMARIN PHARMACEUTICAL INC. · Firm: BIOMARIN PHARMACEUTICAL INC.
H.R. 2507: NEWBORN SCREENING SAVES LIVES REAUTHORIZATION ACT OF 2019; ALL PROVISIONS OF THE BILL H.R. 4439: CREATING HOPE REAUTHORIZATION ACT; ALL PROVISIONS OF THE BILL H.R. 4712: FAIRNESS IN ORPHAN DRUG EXCLUSIVITY ACT; ALL PROVISIONS OF THE BILL H.R. 7567: HELPING EXPERTS ACCELERATE RARE TREATMENTS (HEARTS) ACT OF 2020; ALL PROVISIONS OF THE BILL H.R. 7647: TO PROVIDE FOR A COVID-19-RELATED DELAY REGARDING ANNUAL LIMITATION ON COST-SHARING FOR GROUP HEALTH PLANS AND INDIVIDUAL AND SMALL GROUP HEALTH INSURANCE COVERAGE; ALL PROVISIONS OF THE BILL S. 2158: NEWBORN SCREENING SAVES LIVES REAUTHORIZATION ACT OF 2019; ALL PROVISIONS OF THE BILL S. 4010: CREATING HOPE REAUTHORIZATION ACT; ALL PROVISIONS OF THE BILL GENERAL DISCUSSIONS REGARDING FOOD & DRUG ADMINISTRATION'S COMPLETE RESPONSE LETTER; BREAKTHROUGH THERAPY PROGRAM; HEALTH INNOVATION; NEWBORN SCREENING; VALUE BASED ARRANGEMENTS
The Newborn Screening Saves Lives Reauthorization Act of 2019
Client: BIOMARIN PHARMACEUTICAL INC. · Firm: BIOMARIN PHARMACEUTICAL INC.
H.R. 2507: NEWBORN SCREENING SAVES LIVES REAUTHORIZATION ACT OF 2019; ALL PROVISIONS OF THE BILL H.R. 4439: CREATING HOPE REAUTHORIZATION ACT; ALL PROVISIONS OF THE BILL H.R. 4712: FAIRNESS IN ORPHAN DRUG EXCLUSIVITY ACT; ALL PROVISIONS OF THE BILL H.R. 7567: HELPING EXPERTS ACCELERATE RARE TREATMENTS (HEARTS) ACT OF 2020; ALL PROVISIONS OF THE BILL H.R. 7647: TO PROVIDE FOR A COVID-19-RELATED DELAY REGARDING ANNUAL LIMITATION ON COST-SHARING FOR GROUP HEALTH PLANS AND INDIVIDUAL AND SMALL GROUP HEALTH INSURANCE COVERAGE; ALL PROVISIONS OF THE BILL S. 2158: NEWBORN SCREENING SAVES LIVES REAUTHORIZATION ACT OF 2019; ALL PROVISIONS OF THE BILL S. 4010: CREATING HOPE REAUTHORIZATION ACT; ALL PROVISIONS OF THE BILL GENERAL DISCUSSIONS REGARDING FOOD & DRUG ADMINISTRATION'S COMPLETE RESPONSE LETTER; BREAKTHROUGH THERAPY PROGRAM; HEALTH INNOVATION; NEWBORN SCREENING; VALUE BASED ARRANGEMENTS
The Newborn Screening Saves Lives Reauthorization Act of 2019
Client: BIOMARIN PHARMACEUTICAL INC. · Firm: BIOMARIN PHARMACEUTICAL INC.
H.R. 2507: NEWBORN SCREENING SAVES LIVES REAUTHORIZATION ACT OF 2019; ALL PROVISIONS OF THE BILL H.R. 6238: CAMERON'S LAW; ALL PROVISIONS OF THE BILL S 2158: NEWBORN SCREENING SAVES LIVES REAUTHORIZATION ACT OF 2019; ALL PROVISIONS OF THE BILL GENERAL DISCUSSIONS REGARDING PRESCRIPTION DRUG PRICING AND GENE THERAPY GENERAL DISCUSSIONS REGARDING ORPHAN DRUG ACT
The Newborn Screening Saves Lives Reauthorization Act of 2019
Client: BIOMARIN PHARMACEUTICAL INC. · Firm: BIOMARIN PHARMACEUTICAL INC.
H.R. 2507: NEWBORN SCREENING SAVES LIVES REAUTHORIZATION ACT OF 2019; ALL PROVISIONS OF THE BILL H.R. 4439: CREATING HOPE REAUTHORIZATION ACT; ALL PROVISIONS OF THE BILL S 2158: NEWBORN SCREENING SAVES LIVES REAUTHORIZATION ACT OF 2019; ALL PROVISIONS OF THE BILL S 4010: CREATING HOPE REAUTHORIZATION ACT; ALL PROVISIONS OF THE BILL CONTROLLED SUBSTANCE UTILIZATION REVIEW AND EVALUATION SYSTEM 2.0: GENERAL DISCUSSIONS REGARDING INNOVATION GENERAL DISCUSSIONS REGARDING GENE THERAPY AND OFFICE OF BIOTECHNOLOGY ACTIVITIES GENERAL DISCUSSIONS REGARDING ORPHAN DRUG ACT
A bill for the relief of Maria Isabel Bueso Barrera, Alberto Bueso Mendoza, and Karla Maria Barrera De Bueso.
Client: BIOMARIN PHARMACEUTICAL INC. · Firm: BIOMARIN PHARMACEUTICAL INC.
H.R. 4225: FOR THE RELIEF OF MARIA ISABEL BUESO BARRERA, ALBERTO BUESO MENDOZA, KARLA MARIA BARRERA DE BUESO, AND ANA LUCIA BUESO BARRERA; ALL PROVISIONS OF THE BILL S. 2612: FOR THE RELIEF OF MARIA ISABEL BUESO BARRERA, ALBERTO BUESO MENDOZA, AND KARLA MARIA BARRERA DE BUESO; ALL PROVISIONS OF THE BILL
Creating Hope Reauthorization Act
Client: BIOMARIN PHARMACEUTICAL INC. · Firm: BIOMARIN PHARMACEUTICAL INC.
H.R. 4439: CREATING HOPE REAUTHORIZATION ACT; ALL PROVISIONS OF THE BILL S. 4010: CREATING HOPE REAUTHORIZATION ACT; ALL PROVISIONS OF THE BILL GENERAL DISCUSSIONS REGARDING HEALTH INNOVATION; VALUE BASED ARRANGEMENTS; FDA BREAKTHROUGH THERAPY DESIGNATION AND RESPONSE LETTER; 21ST CENTURY CURES ACT 2.0
Creating Hope Reauthorization Act
Client: BIOMARIN PHARMACEUTICAL INC. · Firm: BIOMARIN PHARMACEUTICAL INC.
H.R. 2507: NEWBORN SCREENING SAVES LIVES REAUTHORIZATION ACT OF 2019; ALL PROVISIONS OF THE BILL H.R. 4439: CREATING HOPE REAUTHORIZATION ACT; ALL PROVISIONS OF THE BILL S 2158: NEWBORN SCREENING SAVES LIVES REAUTHORIZATION ACT OF 2019; ALL PROVISIONS OF THE BILL S 4010: CREATING HOPE REAUTHORIZATION ACT; ALL PROVISIONS OF THE BILL CONTROLLED SUBSTANCE UTILIZATION REVIEW AND EVALUATION SYSTEM 2.0: GENERAL DISCUSSIONS REGARDING INNOVATION GENERAL DISCUSSIONS REGARDING GENE THERAPY AND OFFICE OF BIOTECHNOLOGY ACTIVITIES GENERAL DISCUSSIONS REGARDING ORPHAN DRUG ACT
Creating Hope Reauthorization Act
Client: BIOMARIN PHARMACEUTICAL INC. · Firm: BIOMARIN PHARMACEUTICAL INC.
H.R. 2507: NEWBORN SCREENING SAVES LIVES REAUTHORIZATION ACT OF 2019; ALL PROVISIONS OF THE BILL H.R. 4439: CREATING HOPE REAUTHORIZATION ACT; ALL PROVISIONS OF THE BILL H.R. 4712: FAIRNESS IN ORPHAN DRUG EXCLUSIVITY ACT; ALL PROVISIONS OF THE BILL H.R. 7567: HELPING EXPERTS ACCELERATE RARE TREATMENTS (HEARTS) ACT OF 2020; ALL PROVISIONS OF THE BILL H.R. 7647: TO PROVIDE FOR A COVID-19-RELATED DELAY REGARDING ANNUAL LIMITATION ON COST-SHARING FOR GROUP HEALTH PLANS AND INDIVIDUAL AND SMALL GROUP HEALTH INSURANCE COVERAGE; ALL PROVISIONS OF THE BILL S. 2158: NEWBORN SCREENING SAVES LIVES REAUTHORIZATION ACT OF 2019; ALL PROVISIONS OF THE BILL S. 4010: CREATING HOPE REAUTHORIZATION ACT; ALL PROVISIONS OF THE BILL GENERAL DISCUSSIONS REGARDING FOOD & DRUG ADMINISTRATION'S COMPLETE RESPONSE LETTER; BREAKTHROUGH THERAPY PROGRAM; HEALTH INNOVATION; NEWBORN SCREENING; VALUE BASED ARRANGEMENTS
Medicare Negotiation and Competitive Licensing Act of 2019
Client: BIOMARIN PHARMACEUTICAL INC. · Firm: BIOMARIN PHARMACEUTICAL INC.
H.RES. 242: AFFIRMING THE IMPORTANCE OF THE ORPHAN DRUG ACT, CELEBRATING THE OVER 750 NEW ORPHAN THERAPIES APPROVED SINCE ITS CREATION, AND RECOGNIZING THE NEED TO CONTINUE SUPPORTING RESEARCH AND DEVELOPMENT FOR RARE DISEASE; ALL PROVISIONS OF THE RESOLUTION H.R. 1046: MEDICARE NEGOTIATION AND COMPETITIVE LICENSING ACT OF 2019; ALL PROVISION OF THE BILL S. 377: MEDICARE NEGOTIATION AND COMPETITIVE LICENSING ACT OF 2019; ALL PROVISION OF THE BILL GENERAL DISCUSSIONS REGARDING GENE THERAPY AND VALUE BASED CONTRACTING GENERAL DISCUSSIONS REGARDING NEWBORN SCREENING RE-AUTHORIZATION ACT GENERAL DISCUSSIONS REGARDING THE ORPHAN DRUG ACT GENERAL DISCUSSIONS REGARDING HEALTH CARE FINANCING
H.R. 3: LOWER DRUG COSTS NOW ACT OF 2019; ALL PROVISIONS OF THE BILL H.R. 2069: SPIKE ACT; ALL PROVISIONS OF THE BILL H.R. 2296: MORE EFFICIENT TOOLS TO REALIZE INFORMATION FOR CONSUMERS ACT; ALL PROVISIONS OF THE BILL H.R. 2375: PRESERVE ACCESS TO AFFORDABLE GENERICS AND BIOSIMILARS ACT; ALL PROVISIONS OF THE BILL H.R. 2507: NEWBORN SCREENING SAVES LIVES REAUTHORIZATION ACT OF 2019; ALL PROVISIONS OF THE BILL H.R. 3235: ACCESS TO GENETIC COUNSELOR SERVICES ACT OF 2019; ALL PROVISIONS OF THE BILL H.R. 4439: CREATING HOPE REATHORIZATION ACT; ALL PROVISIONS OF THE BILL S. 2158: NEWBORN SCREENING SAVES LIVES REAUTHORIZATION ACT OF 2019; ALL PROVISIONS OF THE BILL GENERAL DISCUSSIONS REGARDING THE PRESCRIPTION DRUG PRICING REDUCTION ACT'S OUTCOMES BASED AGREEMENTS GENERAL DISCUSSIONS RELATED TO PHENYLKETONURIA (PKU) LOST TO FOLLOW UP
Prescription Drug STAR Act
Client: BIOMARIN PHARMACEUTICAL INC. · Firm: BIOMARIN PHARMACEUTICAL INC.
H.R. 2113: PRESCRIPTION DRUG STAR ACT; ALL PROVISIONS OF THE BILL H.R. 2296: FAIR DRUG PRICING ACT OF 2019; ALL PROVISIONS OF THE BILL H.R. 2507: NEWBORN SCREENING SAVES LIVES REAUTHORIZATION ACT OF 2019; ALL PROVISIONS OF THE BILL S 474: STOPPING THE PHARMACEUTICAL INDUSTRY FROM KEEPING DRUGS EXPENSIVE (SPIKE) ACT OF 2019; ALL PROVISIONS OF THE BILL S. 1391 FAIR ACCOUNTABILITY AND INNOVATIVE RESEARCH (FAIR) DRUG PRICING ACT OF 2019; ALL PROVISIONS OF THE BILL GENERAL DISCUSSIONS REGARDING GENE THERAPY GENERAL DISCUSSIONS REGARDING THE ORPHAN DRUG ACT AND TAX CREDIT (NOT YET INTRODUCED) GENERAL DISCUSSIONS REGARDING PATIENT AFFORDABILITY, VALUE & EFFICIENCY (PAVE) ACT; ALL PROVISIONS OF THE DRAFT
More Efficient Tools to Realize Information for Consumers Act
Client: BIOMARIN PHARMACEUTICAL INC. · Firm: BIOMARIN PHARMACEUTICAL INC.
H.R. 3: LOWER DRUG COSTS NOW ACT OF 2019; ALL PROVISIONS OF THE BILL H.R. 2069: SPIKE ACT; ALL PROVISIONS OF THE BILL H.R. 2296: MORE EFFICIENT TOOLS TO REALIZE INFORMATION FOR CONSUMERS ACT; ALL PROVISIONS OF THE BILL H.R. 2375: PRESERVE ACCESS TO AFFORDABLE GENERICS AND BIOSIMILARS ACT; ALL PROVISIONS OF THE BILL H.R. 2507: NEWBORN SCREENING SAVES LIVES REAUTHORIZATION ACT OF 2019; ALL PROVISIONS OF THE BILL H.R. 3235: ACCESS TO GENETIC COUNSELOR SERVICES ACT OF 2019; ALL PROVISIONS OF THE BILL H.R. 4439: CREATING HOPE REATHORIZATION ACT; ALL PROVISIONS OF THE BILL S. 2158: NEWBORN SCREENING SAVES LIVES REAUTHORIZATION ACT OF 2019; ALL PROVISIONS OF THE BILL GENERAL DISCUSSIONS REGARDING THE PRESCRIPTION DRUG PRICING REDUCTION ACT'S OUTCOMES BASED AGREEMENTS GENERAL DISCUSSIONS RELATED TO PHENYLKETONURIA (PKU) LOST TO FOLLOW UP
GENERAL DISCUSSIONS REGARDING MEDICAID GENERAL DISCUSSIONS REGARDING NEWBORN SCREENING GENERAL DISCUSSIONS REGARDING ORPHAN DRUGS GENERAL DISCUSSIONS REGARDING PATIENT EXPERIENCE DATA GENERAL DISCUSSIONS REGARDING RECOMMENDED UNIFORM SCREENING PANEL (RUSP) CONDITION ADDITION GENERAL DISCUSSIONS REGARDING GENETIC SCREENING AND TESTING
Filing targets: HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Health Resources & Services Administration (HRSA), SENATE
BIOMARIN PHARMACEUTICAL INC. via BIOMARIN PHARMACEUTICAL INC.
2026 · second_quarter · 2A
GENERAL DISCUSSIONS REGARDING MEDICAID GENERAL DISCUSSIONS REGARDING NEWBORN SCREENING GENERAL DISCUSSIONS REGARDING ORPHAN DRUGS GENERAL DISCUSSIONS REGARDING PATIENT EXPERIENCE DATA GENERAL DISCUSSIONS REGARDING RECOMMENDED UNIFORM SCREENING PANEL (RUSP) CONDITION ADDITION GENERAL DISCUSSIONS REGARDING GENETIC SCREENING AND TESTING
GENERAL DISCUSSIONS REGARDING TARDE
GENERAL DISCUSSIONS RELATED TO MOST-FAVORED-NATION (MFN) FOREIGN REFERENCE PRICING GENERAL DISCUSSIONS REGARDING MEDICAID PRIOR AUTHORIZATION GENERAL DISCUSSIONS REGARDING UTILIZATION MANAGEMENT
Filing targets: HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Health Resources & Services Administration (HRSA), SENATE
BIOMARIN PHARMACEUTICAL INC. via BIOMARIN PHARMACEUTICAL INC.
2026 · second_quarter · Q2
GENERAL DISCUSSIONS REGARDING MEDICAID GENERAL DISCUSSIONS REGARDING NEWBORN SCREENING GENERAL DISCUSSIONS REGARDING ORPHAN DRUGS GENERAL DISCUSSIONS REGARDING PATIENT EXPERIENCE DATA GENERAL DISCUSSIONS REGARDING RECOMMENDED UNIFORM SCREENING PANEL (RUSP) CONDITION ADDITION GENERAL DISCUSSIONS REGARDING GENETIC SCREENING AND TESTING
GENERAL DISCUSSIONS REGARDING TARDE
GENERAL DISCUSSIONS RELATED TO MOST-FAVORED-NATION (MFN) FOREIGN REFERENCE PRICING GENERAL DISCUSSIONS REGARDING MEDICAID PRIOR AUTHORIZATION GENERAL DISCUSSIONS REGARDING UTILIZATION MANAGEMENT
Filing targets: HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Health Resources & Services Administration (HRSA), SENATE
BIOMARIN PHARMACEUTICAL INC. via BIOMARIN PHARMACEUTICAL INC.
2026 · first_quarter · Q1
GENERAL DISCUSSIONS REGARDING GENETIC TESTING AND NEWBORN SCREENING GENERAL DISCUSSIONS REGARDING ORPHAN DRUGS GENERAL DISCUSSIONS RELATED TO THE PRIORITY REVIEW VOUCHER PROGRAM EXTENSION GENERAL DISCUSSIONS RELATED TO TARIFFS ON PHARMACEUTICALS GENERAL DISCUSSIONS RELATED TO METABOLIC DISORDER PUBLIC HEALTH CAMPAIGN GENERAL DISCUSSIONS RELATED TO RARE DISEASE DRUG DEVELOPMENT
Filing targets: Commerce, Dept of (DOC), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
BIOMARIN PHARMACEUTICAL INC. via BIOMARIN PHARMACEUTICAL INC.
2025 · fourth_quarter · Q4
H.R.1262: GIVE KIDS A CHANCE ACT OF 2025; PROVISIONS RELATED TO RARE PEDIATRIC DISEASE PRIORITY REVIEW VOUCHER PROGRAM REAUTHORIZATION S.932: GIVE KIDS A CHANCE ACT OF 2025; PROVISIONS RELATED TO RARE PEDIATRIC DISEASE PRIORITY REVIEW VOUCHER PROGRAM REAUTHORIZATION GENERAL DISCUSSIONS REGARDING GENETIC SREENING AND NEWBORN SREENING GENERAL DISCUSSIONS REGARDING ORPHAN DRUGS GENERAL DISCUSSIONS RELATED TO MOST-FAVORED-NATION (MFN) DRUG PRICING GENERAL DISCUSSIONS RELATED TO THE PRIORITY REVIEW VOUCHER PROGRAM
Filing targets: Commerce, Dept of (DOC), Executive Office of the President (EOP), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
BIOMARIN PHARMACEUTICAL INC. via BIOMARIN PHARMACEUTICAL INC.
2025 · third_quarter · Q3
GENERAL DISCUSSIONS REGARDING ORPHAN DRUG EXCLUSIVITY
H.R.1262: GIVE KIDS A CHANCE ACT OF 2025; PROVISIONS RELATED TO RARE PEDIATRIC DISEASE PRIORITY REVIEW VOUCHER PROGRAM REAUTHORIZATION S.932: GIVE KIDS A CHANCE ACT OF 2025; PROVISIONS RELATED TO RARE PEDIATRIC DISEASE PRIORITY REVIEW VOUCHER PROGRAM REAUTHORIZATION GENERAL DISCUSSIONS REGARDING GENETIC SREENING AND NEWBORN SREENING GENERAL DISCUSSIONS REGARDING ORPHAN DRUGS GENERAL DISCUSSIONS RELATED TO MOST-FAVORED-NATION (MFN) DRUG PRICING GENERAL DISCUSSIONS RELATED TO THE PRIORITY REVIEW VOUCHER PROGRAM
GENERAL DISCUSSIONS REGARDING TARIFFS ON PHARMACEUTICALS
Filing targets: Commerce, Dept of (DOC), HOUSE OF REPRESENTATIVES, SENATE
BIOMARIN PHARMACEUTICAL INC. via BIOMARIN PHARMACEUTICAL INC.
2025 · second_quarter · Q2
HR 1262: GIVE KIDS A CHANCE ACT OF 2025; PROVISIONS RELATED TO RARE PEDIATRIC DISEASE PRIORITY REVIEW VOUCHER PROGRAM REAUTHORIZATION S 932: GIVE KIDS A CHANCE ACT OF 2025; PROVISIONS RELATED TO RARE PEDIATRIC DISEASE PRIORITY REVIEW VOUCHER PROGRAM REAUTHORIZATION GENERAL DISCUSSIONS REGARDING INFLATION REDUCTION ACT AND ORPHAN DRUGS GENERAL DISCUSSIONS REGARDING ORPHAN DRUG ACT GENERAL DISCUSSIONS REGARDING GENETIC SCREENING AND NEWBORN SCREENING
Filing targets: Commerce, Dept of (DOC), HOUSE OF REPRESENTATIVES, SENATE
BIOMARIN PHARMACEUTICAL INC. via BIOMARIN PHARMACEUTICAL INC.
2025 · first_quarter · Q1
HR 1262: GIVE KIDS A CHANCE ACT OF 2025; PROVISIONS RELATED TO RARE PEDIATRIC DISEASE PRIORITY REVIEW VOUCHER PROGRAM REAUTHORIZATION S 932: GIVE KIDS A CHANCE ACT OF 2025; PROVISIONS RELATED TO RARE PEDIATRIC DISEASE PRIORITY REVIEW VOUCHER PROGRAM REAUTHORIZATION GENERAL DISCUSSIONS REGARDING ORPHAN DRUG ACT, HEALTH AND HUMAN SERVICES (HHS) RESTRUCTURING, MANUFACTURER-SPONSORED GENETIC SCREENING, PRIORITY REVIEW VOUCHER (PRV) EXTENSION, MEDICAID, NEWBORN SCREENING
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
BIOMARIN PHARMACEUTICAL INC. via BIOMARIN PHARMACEUTICAL INC.
2024 · fourth_quarter · Q4
HR 830: HELP ENSURE LOWER PATIENT (HELP) COPAYS ACT; ALL PROVISIONS OF THE BILL HR 2630: SAFE STEP ACT; ALL PROVISIONS OF THE BILL HR 2666: MEDICAID VBPS FOR PATIENTS ACT (MVP ACT); PROVISIONS RELATED TO OUTCOME BASED ARRANGEMENTS (OBA) AND VALUE BASED ARRANGEMENTS (VBA) HR 4758: ACCELERATING KIDS' ACCESS TO CARE ACT: ALL PROVISIONS OF THE BILL HR 7384: CREATING HOPE REAUTHORIZATION ACT OF 2024; ALL PROVISIONS OF THE BILL HR 8574: 340B AFFORDABLE CARE FOR COMMUNITIES AND ENSURING A STRONG SAFETY-NET (ACCESS) ACT; ALL PROVISIONS OF THE BILL HR 9184: PATIENT ACCESS ACT OF 2024; ALL PROVISIONS OF THE BILL S 2372: ACCELERATING KIDS' ACCESS TO CARE ACT; ALL PROVISIONS OF THE BILL S 4583: CREATING HOPE REAUTHORIZATION ACT OF 2024; ALL PROVISIONS OF THE BILL GENERAL DISCUSSIONS REGARDING GENETIC SCREENING, LONG TERM FOLLOW UP, CURES 3.0, AND ORPHAN DRUG ACT
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
BIOMARIN PHARMACEUTICAL INC. via BIOMARIN PHARMACEUTICAL INC.
2024 · third_quarter · Q3
HR 830: HELP ENSURE LOWER PATIENT (HELP) COPAYS ACT; ALL PROVISIONS OF THE BILL HR 2630: SAFE STEP ACT; ALL PROVISIONS OF THE BILL HR 2666: MEDICAID VBPS FOR PATIENTS ACT (MVP ACT); PROVISIONS RELATED TO OUTCOME BASED ARRANGEMENTS (OBA) AND VALUE BASED ARRANGEMENTS (VBA) HR 7384: CREATING HOPE REAUTHORIZATION ACT OF 2024; ALL PROVISIONS OF THE BILL HR 8574: 340B AFFORDABLE CARE FOR COMMUNITIES AND ENSURING A STRONG SAFETY-NET (ACCESS) ACT; ALL PROVISIONS OF THE BILL HR 9184: PATIENT ACCESS ACT OF 2024; ALL PROVISIONS OF THE BILL S 4583: CREATING HOPE REAUTHORIZATION ACT OF 2024; ALL PROVISIONS OF THE BILL GENERAL DISCUSSIONS REGARDING GENETIC SCREENING, LONG TERM FOLLOW UP, CURES 3.0
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
BIOMARIN PHARMACEUTICAL INC. via BIOMARIN PHARMACEUTICAL INC.
2024 · second_quarter · Q2
HR 830: HELP ENSURE LOWER PATIENT COPAYS ACT; ALL PROVISIONS OF THE BILL HR 2369: VERIFYING ACCURATE LEADING-EDGE IVCT DEVELOPMENT ACT OF 2023; ALL PROVISIONS OF THE BILL HR 2630: SAFE STEP ACT; ALL PROVISIONS OF THE BILL HR 2666: MEDICAID VBPS FOR PATIENTS ACT (MVP ACT); PROVISIONS RELATED TO OUTCOME BASED ARRANGEMENTS (OBA) AND VALUE BASED ARRANGEMENTS (VBA) HR 5539: OPTIMIZING RESEARCH PROGRESS HOPE AND NEW CURES ACT (ORPHAN CURES ACT); ALL PROVISIONS OF THE BILL HR 7384: CREATING HOPE REAUTHORIZATION ACT OF 2024; ALL PROVISIONS OF THE BILL S 4583: A BILL TO AMEND THE FEDERAL FOOD, DRUG, AND COSMETIC ACT TO EXTEND THE AUTHORITY OF THE SECRETARY OF HEALTH AND HUMAN SERVICES TO ISSUE PRIORITY REVIEW VOUCHERS TO ENCOURAGE TREATMENTS FOR RARE PEDIATRIC DISEASES; ALL PROVISIONS OF THE BILL GENERAL DISCUSSIONS REGARDING HEALTH EQUITY
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
BIOMARIN PHARMACEUTICAL INC. via BIOMARIN PHARMACEUTICAL INC.
2024 · first_quarter · Q1
HR 2666: MEDICAID VBPS FOR PATIENTS ACT (MVP ACT); PROVISIONS RELATED TO OUTCOME BASED ARRANGEMENTS (OBA) AND VALUE BASED ARRANGEMENTS (VBA) HR 5539: OPTIMIZING RESEARCH PROGRESS HOPE AND NEW CURES ACT (ORPHAN CURES ACT); ALL PROVISIONS OF THE BILL HR 7384: CREATING HOPE REAUTHORIZATION ACT OF 2024: ALL PROVISIONS OF THE BILL HR 7635: THE 340B PHARMACEUTICAL ACCESS TO INVEST IN ESSENTIAL, NEEDED TREATMENTS & SUPPORT ACT OF 2024 (PATIENTS ACT); ALL PROVISIONS OF THE BILL GENERAL DISCUSSIONS REGARDING HEMOPHILIA GENE THERAPY
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
BIOMARIN PHARMACEUTICAL INC. via BIOMARIN PHARMACEUTICAL INC.
2023 · fourth_quarter · Q4
HR 2369: VALID ACT OF 2023; ALL PROVISIONS OF THE BILL HR 2666: MEDICAID VBPS FOR PATIENTS ACT (MVP ACT); PROVISIONS RELATED TO OUTCOME BASED ARRANGEMENTS (OBA) AND VALUE BASED ARRANGEMENTS (VBA) HR 4408: PROMISING PATHWAY ACT; ALL PROVISIONS OF THE BILL S 1906: PROMISING PATHWAY ACT; ALL PROVISIONS OF THE BILL GENERAL DISCUSSIONS REGARDING 340B DRUG PRICING PROGRAM REFORM, RARE DISEASE GENE THERAPY ACCESS, CENTERS FOR MEDICARE & MEDICAID SERVICES (CMS) PROPOSED PRICE JUSTIFICATION SURVEY, HEMOPHILIA GENE THERAPY, RARE DISEASE DRUG DEVELOPMENT
Filing targets: Government Accountability Office (GAO), HOUSE OF REPRESENTATIVES, SENATE
BIOMARIN PHARMACEUTICAL INC. via BIOMARIN PHARMACEUTICAL INC.
2023 · third_quarter · Q3
GENERAL DISCUSSIONS REGARDING HEMOPHILIA GENE THERAPY, RARE DISEASE EXPERTS ON FOOD AND DRUG ADMINISTRATION REVIEW TEAMS, RARE DISEASE DIAGNOSIS, AND OUTCOME BASED ARRANGEMENTS (OBA) AND VALUE BASED ARRANGEMENTS (VBA)
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
BIOMARIN PHARMACEUTICAL INC. via BIOMARIN PHARMACEUTICAL INC.
2023 · second_quarter · Q2
GENERAL DISCUSSIONS REGARDING HEMOPHILIA GENE THERAPY GENERAL DISCUSSIONS REGARDING VALUE BASED ARRANGEMENTS (VBA)
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
BIOMARIN PHARMACEUTICAL INC. via BIOMARIN PHARMACEUTICAL INC.
2023 · first_quarter · Q1
GENERAL DISCUSSIONS REGARDING HEMOPHILIA GENE THERAPY GENERAL DISCUSSIONS REGARDING OUTCOME BASED ARRANGEMENTS (OBA) AND VALUE BASED ARRANGEMENTS (VBA)
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
BIOMARIN PHARMACEUTICAL INC. via BIOMARIN PHARMACEUTICAL INC.
2022 · fourth_quarter · Q4
HR 482: NEWBORN SCREENING SAVES LIVES REAUTHORIZATION ACT OF 2021; ALL PROVISIONS OF THE BILL (HR 2617) P.L. 117-328: CONSOLIDATED APPROPRIATIONS ACT, 2023: PROVISIONS RELATED TO SECTIONS 3107, 3202, 3210, 3601-3607, 3629 S 350: NEWBORN SCREENING SAVES LIVES REAUTHORIZATION ACT OF 2021; ALL PROVISIONS OF THE BILL GENERAL DISCUSSIONS REGARDING FEDERAL DRUG ADMINISTRATION AND EUROPEAN MEDICINES AGENCY DRUG APPROVAL GENERAL DISCUSSIONS REGARDING ANTI-KICKBACK SAFE HARBOR FOR PATIENT TRAVEL COSTS GENERAL DISCUSSIONS REGARDING BUDGET RIDERS, ORPHAN DRUG ACT TAX CREDIT, AND VETERANS BENEFITS ADMINISTRATION
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
BIOMARIN PHARMACEUTICAL INC. via BIOMARIN PHARMACEUTICAL INC.
2022 · third_quarter · Q3
HR 482: NEWBORN SCREENING SAVES LIVES REAUTHORIZATION ACT OF 2021; ALL PROVISIONS OF THE BILL HR 7667: FOOD AND DRUG AMENDMENTS OF 2022; PROVISIONS RELATED TO TITLE V, SECTIONS 703 AND 804 S 350: NEWBORN SCREENING SAVES LIVES REAUTHORIZATION ACT OF 2021; ALL PROVISIONS OF THE BILL S 4348: FOOD AND DRUG ADMINISTRATION SAFETY AND LANDMARK ADVANCEMENTS ACT OF 2022 (FDASLA ACT); PROVISIONS RELATED TO SECTION 506 GENERAL DISCUSSIONS REGARDING RARE DISEASES AND VETERANS BENEFITS ADMINISTRATIONS
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
BIOMARIN PHARMACEUTICAL INC. via BIOMARIN PHARMACEUTICAL INC.
2022 · second_quarter · Q2
HR 5376: BUILD BACK BETTER ACT; PROVISIONS RELATED TO THE ORPHAN DRUG ACT
HR 4472: BETTER EMPOWERMENT NOW TO ENHANCE FRAMEWORK AND IMPROVE TREATMENTS (BENEFIT) ACT OF 2021; ALL PROVISIONS OF THE BILL HR 6000: CURES 2.0 ACT: PROVISIONS RELATED TO SECTIONS 203, 204, 303-309, 402, 403, 407 HR 6584: DIVERSE AND EQUITABLE PARTICIPATION IN CLINICAL TRIALS (DEPICT) ACT; ALL PROVISIONS OF THE BILL HR 6888: HELPING EXPERTS ACCELERATE RARE TREATMENTS ACT OF 2022; ALL PROVISIONS OF THE BILL HR 6963: ACCELERATED APPROVAL INTEGRITY ACT OF 2022; ALL PROVISIONS OF THE BILL HR 6996: ACCELERATING ACCESS FOR PATIENTS ACT OF 2022; ALL PROVISIONS OF THE BILL HR 7667: FOOD AND DRUG AMENDMENTS OF 2022; PROVISIONS RELATED TO TITLE V, SECTIONS 703 AND 804 S 373: BETTER EMPOWERMENT NOW TO ENHANCE FRAMEWORK AND IMPROVE TREATMENTS (BENEFIT) ACT OF 2021; ALL PROVISIONS OF THE BILL S 4071: HELPING EXPERTS ACCELERATE RARE TREATMENTS ACT OF 2022; ALL PROVISIONS OF THE BILL S 4348: FOOD AND DRUG ADMINISTRATION SAFETY AND LANDMARK ADVANCEMENTS ACT OF 2022 (FDASLA ACT); PROVISIONS RELATED TO SECTION 506 GENERAL DISCUSSIONS REGARDING ISSUES AFFECTING GENETIC BONE DISORDERS GENERAL DISCUSSIONS REGARDING HEMOPHILIA GENE THERAPY
BIOMARIN PHARMACEUTICAL INC. via BIOMARIN PHARMACEUTICAL INC.
2022 · first_quarter · Q1
HR 4472: BETTER EMPOWERMENT NOW TO ENHANCE FRAMEWORK AND IMPROVE TREATMENTS (BENEFIT) ACT OF 2021; ALL PROVISIONS OF THE BILL HR 6000: CURES 2.0 ACT: PROVISIONS RELATED TO SECTIONS 203, 204, 303-309, 402, 403, 407 HR 6584: DIVERSE AND EQUITABLE PARTICIPATION IN CLINICAL TRIALS (DEPICT) ACT; ALL PROVISIONS OF THE BILL HR 6888: HELPING EXPERTS ACCELERATE RARE TREATMENTS (HEART) ACT OF 2022; ALL PROVISIONS OF THE BILL HR 6963: ACCELERATED APPROVAL INTEGRITY ACT OF 2022; ALL PROVISIONS OF THE BILL HR 6996: ACCELERATING ACCESS FOR PATIENTS ACT OF 2022: ALL PROVISIONS OF THE BILL S 373: BETTER EMPOWERMENT NOW TO ENHANCE FRAMEWORK AND IMPROVE TREATMENTS (BENEFIT) ACT OF 2021; ALL PROVISIONS OF THE BILL GENERAL DISCUSSIONS REGARDING VALUE-BASED PAYMENT ARRANGEMENTS (VBA)
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
BIOMARIN PHARMACEUTICAL INC. via BIOMARIN PHARMACEUTICAL INC.
2021 · fourth_quarter · Q4
HR 2623: CAMERON'S LAW; ALL PROVISIONS OF THE BILL HR 5376: BUILD BACK BETTER ACT; PROVISIONS RELATED TO SECTIONS 138121, 138126, 138127, 138141, 139001, 139101, 139102, 139201, AND THE ORPHAN DRUG ACT TAX CREDIT
HR 842: NEWBORN SCREENING SAVES LIVES REAUTHORIZATION ACT OF 2021; ALL PROVISIONS OF THE BILL HR 6000: CURES 2.0 ACT: PROVISIONS RELATED TO SECTIONS 203, 204, 303-309, 402, 403, 407, AND RARE DISEASES S 350: NEWBORN SCREENING SAVES LIVES REAUTHORIZATION ACT OF 2021; ALL PROVISIONS OF THE BILL GENERAL DISCUSSIONS REGARDING THE 21ST CENTURY CURES ACT 2.0
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
BIOMARIN PHARMACEUTICAL INC. via BIOMARIN PHARMACEUTICAL INC.
2021 · third_quarter · Q3
HR 2623: CAMERON'S LAW; ALL PROVISIONS OF THE BILL HR 5376: BUILD BACK BETTER ACT; PROVISIONS RELATED TO SECTION 138141 GENERAL DISCUSSIONS REGARDING THE ORPHAN DRUG ACT
HR 482: NEWBORN SCREENING SAVES LIVES REAUTHORIZATION ACT OF 2021; ALL PROVISIONS OF THE BILL S 350: NEWBORN SCREENING SAVES LIVES REAUTHORIZATION ACT OF 2021; ALL PROVISIONS OF THE BILL GENERAL DISCUSSIONS RELATED TO THE 21ST CENTURY CURES ACT 2.0 GENERAL DISCUSSIONS RELATED TO THE OUTCOME-BASED ARRANGEMENTS
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
BIOMARIN PHARMACEUTICAL INC. via BIOMARIN PHARMACEUTICAL INC.
2021 · second_quarter · Q2
HR 482: NEWBORN SCREENING SAVES LIVES REAUTHORIZATION ACT OF 2021; ALL PROVISIONS OF THE BILL HR 1184: HELPING EXPERTS ACCELERATE RARE TREATMENTS (HEART) ACT OF 2021; ALL PROVISIONS OF THE BILL S 350: NEWBORN SCREENING SAVES LIVES REAUTHORIZATION ACT OF 2021; ALL PROVISIONS OF THE BILL S 373: BENEFIT ACT OF 2021; PROVISIONS RELATED TO RARE DISEASES S 2164: LOWER COSTS, MORE CURES ACT OF 2021; PROVISIONS RELATED TO VALUE BASED ARRANGEMENTS GENERAL DISCUSSIONS RELATED TO THE 21ST CENTURY CURES ACT 2.0 GENERAL DISCUSSIONS RELATED TO THE ORPHAN DRUG ACT
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
BIOMARIN PHARMACEUTICAL INC. via BIOMARIN PHARMACEUTICAL INC.
2021 · first_quarter · Q1
GENERAL DISCUSSIONS REGARDING THE VALUE BASED ARRANGEMENTS AND ORPHAN DRUG ACT GENERAL DISCUSSIONS REGARDING CENTER OF DISEASE CONTROL APPROPRIATIONS FOR LONG-TERM FOLLOW-UP FOR METABOLIC DISORDERS
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
BIOMARIN PHARMACEUTICAL INC. via BIOMARIN PHARMACEUTICAL INC.
2020 · fourth_quarter · Q4
H.R. 4439: CREATING HOPE REAUTHORIZATION ACT; ALL PROVISIONS OF THE BILL S. 4010: CREATING HOPE REAUTHORIZATION ACT; ALL PROVISIONS OF THE BILL GENERAL DISCUSSIONS REGARDING HEALTH INNOVATION; VALUE BASED ARRANGEMENTS; FDA BREAKTHROUGH THERAPY DESIGNATION AND RESPONSE LETTER; 21ST CENTURY CURES ACT 2.0
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
BIOMARIN PHARMACEUTICAL INC. via BIOMARIN PHARMACEUTICAL INC.
2020 · third_quarter · Q3
H.R. 4225: FOR THE RELIEF OF MARIA ISABEL BUESO BARRERA, ALBERTO BUESO MENDOZA, KARLA MARIA BARRERA DE BUESO, AND ANA LUCIA BUESO BARRERA; ALL PROVISIONS OF THE BILL S. 2612: FOR THE RELIEF OF MARIA ISABEL BUESO BARRERA, ALBERTO BUESO MENDOZA, AND KARLA MARIA BARRERA DE BUESO; ALL PROVISIONS OF THE BILL
H.R. 2507: NEWBORN SCREENING SAVES LIVES REAUTHORIZATION ACT OF 2019; ALL PROVISIONS OF THE BILL H.R. 4439: CREATING HOPE REAUTHORIZATION ACT; ALL PROVISIONS OF THE BILL H.R. 4712: FAIRNESS IN ORPHAN DRUG EXCLUSIVITY ACT; ALL PROVISIONS OF THE BILL H.R. 7567: HELPING EXPERTS ACCELERATE RARE TREATMENTS (HEARTS) ACT OF 2020; ALL PROVISIONS OF THE BILL H.R. 7647: TO PROVIDE FOR A COVID-19-RELATED DELAY REGARDING ANNUAL LIMITATION ON COST-SHARING FOR GROUP HEALTH PLANS AND INDIVIDUAL AND SMALL GROUP HEALTH INSURANCE COVERAGE; ALL PROVISIONS OF THE BILL S. 2158: NEWBORN SCREENING SAVES LIVES REAUTHORIZATION ACT OF 2019; ALL PROVISIONS OF THE BILL S. 4010: CREATING HOPE REAUTHORIZATION ACT; ALL PROVISIONS OF THE BILL GENERAL DISCUSSIONS REGARDING FOOD & DRUG ADMINISTRATION'S COMPLETE RESPONSE LETTER; BREAKTHROUGH THERAPY PROGRAM; HEALTH INNOVATION; NEWBORN SCREENING; VALUE BASED ARRANGEMENTS
BIOMARIN PHARMACEUTICAL INC. via BIOMARIN PHARMACEUTICAL INC.
2020 · second_quarter · Q2
H.R. 2507: NEWBORN SCREENING SAVES LIVES REAUTHORIZATION ACT OF 2019; ALL PROVISIONS OF THE BILL H.R. 4439: CREATING HOPE REAUTHORIZATION ACT; ALL PROVISIONS OF THE BILL S 2158: NEWBORN SCREENING SAVES LIVES REAUTHORIZATION ACT OF 2019; ALL PROVISIONS OF THE BILL S 4010: CREATING HOPE REAUTHORIZATION ACT; ALL PROVISIONS OF THE BILL CONTROLLED SUBSTANCE UTILIZATION REVIEW AND EVALUATION SYSTEM 2.0: GENERAL DISCUSSIONS REGARDING INNOVATION GENERAL DISCUSSIONS REGARDING GENE THERAPY AND OFFICE OF BIOTECHNOLOGY ACTIVITIES GENERAL DISCUSSIONS REGARDING ORPHAN DRUG ACT
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
BIOMARIN PHARMACEUTICAL INC. via BIOMARIN PHARMACEUTICAL INC.
2020 · first_quarter · Q1
H.R. 2507: NEWBORN SCREENING SAVES LIVES REAUTHORIZATION ACT OF 2019; ALL PROVISIONS OF THE BILL H.R. 6238: CAMERON'S LAW; ALL PROVISIONS OF THE BILL S 2158: NEWBORN SCREENING SAVES LIVES REAUTHORIZATION ACT OF 2019; ALL PROVISIONS OF THE BILL GENERAL DISCUSSIONS REGARDING PRESCRIPTION DRUG PRICING AND GENE THERAPY GENERAL DISCUSSIONS REGARDING ORPHAN DRUG ACT
Filing targets: HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
BIOMARIN PHARMACEUTICAL INC. via BIOMARIN PHARMACEUTICAL INC.
2019 · fourth_quarter · Q4
H.R. 2507: NEWBORN SCREENING SAVES LIVES REAUTHORIZATION ACT OF 2019; ALL PROVISIONS OF THE BILL H.R. 4225: A BILL FOR THE RELIEF OF MARIA ISABEL BUESO BARRERA, ALBERTO BUESO MENDOZA, KARLA MARIA BARRERA DE BUESO AND ANA LUCIA BUESO BARRERA; PROVISIONS RELATED TO EXTEND DEFERRED PROGRAM H.R. 4667: BIOMEDICAL INNOVATION EXPANSION ACT OF 2019; PROVISIONS RELATED TO NATIONAL INSTITUTES OF HEALTH FUNDING FOR RARE DISEASE RESEARCH H.R. 4712: FAIRNESS IN ORPHAN DRUG EXCLUSIVITY ACT: ALL PROVISIONS OF THE BILL S 2158: NEWBORN SCREENING SAVES LIVES REAUTHORIZATION ACT OF 2019; ALL PROVISIONS OF THE BILL S 2612: A BILL FOR THE RELIEF OF MARIA ISABEL BUESO BARRERA, ALBERTO BUESO MENDOZA AND KARLA MARIA BARRERA DE BUESO; PROVISIONS RELATED TO EXTEND DEFERRED PROGRAM GENERAL DISCUSSIONS REGARDING GENE THERAPY GENERAL DISCUSSIONS REGARDING ORPHAN DRUG ACT GENERAL DISCUSSIONS REGARDING PHENYLKETONURIA (PKU) LOST TO FOLLOW UP GENERAL DISCUSSIONS REGARDING 21ST CENTURY CURES 2.0; PROVISIONS RELATED TO PATIENT ACCESS TO INNOVATION THERAPIES
BIOMARIN PHARMACEUTICAL INC. via BIOMARIN PHARMACEUTICAL INC.
2019 · third_quarter · Q3
H.R. 3: LOWER DRUG COSTS NOW ACT OF 2019; ALL PROVISIONS OF THE BILL H.R. 2069: SPIKE ACT; ALL PROVISIONS OF THE BILL H.R. 2296: MORE EFFICIENT TOOLS TO REALIZE INFORMATION FOR CONSUMERS ACT; ALL PROVISIONS OF THE BILL H.R. 2375: PRESERVE ACCESS TO AFFORDABLE GENERICS AND BIOSIMILARS ACT; ALL PROVISIONS OF THE BILL H.R. 2507: NEWBORN SCREENING SAVES LIVES REAUTHORIZATION ACT OF 2019; ALL PROVISIONS OF THE BILL H.R. 3235: ACCESS TO GENETIC COUNSELOR SERVICES ACT OF 2019; ALL PROVISIONS OF THE BILL H.R. 4439: CREATING HOPE REATHORIZATION ACT; ALL PROVISIONS OF THE BILL S. 2158: NEWBORN SCREENING SAVES LIVES REAUTHORIZATION ACT OF 2019; ALL PROVISIONS OF THE BILL GENERAL DISCUSSIONS REGARDING THE PRESCRIPTION DRUG PRICING REDUCTION ACT'S OUTCOMES BASED AGREEMENTS GENERAL DISCUSSIONS RELATED TO PHENYLKETONURIA (PKU) LOST TO FOLLOW UP
GENERAL DISCUSSIONS REGARDING DEFERRED ACTION FOR MEDICAL AND DEFERRED ACTION PROGRAM
Filing targets: HOUSE OF REPRESENTATIVES, Homeland Security, Dept of (DHS), SENATE, U.S. Immigration & Customs Enforcement (ICE)
BIOMARIN PHARMACEUTICAL INC. via BIOMARIN PHARMACEUTICAL INC.
2019 · second_quarter · Q2
GENERAL DISCUSSIONS REGARDING MEDICAID PROVISIONS AND PROVISIONS ON VETERANS BENEFITS ADMINISTRATION
H.R. 2113: PRESCRIPTION DRUG STAR ACT; ALL PROVISIONS OF THE BILL H.R. 2296: FAIR DRUG PRICING ACT OF 2019; ALL PROVISIONS OF THE BILL H.R. 2507: NEWBORN SCREENING SAVES LIVES REAUTHORIZATION ACT OF 2019; ALL PROVISIONS OF THE BILL S 474: STOPPING THE PHARMACEUTICAL INDUSTRY FROM KEEPING DRUGS EXPENSIVE (SPIKE) ACT OF 2019; ALL PROVISIONS OF THE BILL S. 1391 FAIR ACCOUNTABILITY AND INNOVATIVE RESEARCH (FAIR) DRUG PRICING ACT OF 2019; ALL PROVISIONS OF THE BILL GENERAL DISCUSSIONS REGARDING GENE THERAPY GENERAL DISCUSSIONS REGARDING THE ORPHAN DRUG ACT AND TAX CREDIT (NOT YET INTRODUCED) GENERAL DISCUSSIONS REGARDING PATIENT AFFORDABILITY, VALUE & EFFICIENCY (PAVE) ACT; ALL PROVISIONS OF THE DRAFT
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
BIOMARIN PHARMACEUTICAL INC. via BIOMARIN PHARMACEUTICAL INC.
2019 · first_quarter · Q1
H.RES. 242: AFFIRMING THE IMPORTANCE OF THE ORPHAN DRUG ACT, CELEBRATING THE OVER 750 NEW ORPHAN THERAPIES APPROVED SINCE ITS CREATION, AND RECOGNIZING THE NEED TO CONTINUE SUPPORTING RESEARCH AND DEVELOPMENT FOR RARE DISEASE; ALL PROVISIONS OF THE RESOLUTION H.R. 1046: MEDICARE NEGOTIATION AND COMPETITIVE LICENSING ACT OF 2019; ALL PROVISION OF THE BILL S. 377: MEDICARE NEGOTIATION AND COMPETITIVE LICENSING ACT OF 2019; ALL PROVISION OF THE BILL GENERAL DISCUSSIONS REGARDING GENE THERAPY AND VALUE BASED CONTRACTING GENERAL DISCUSSIONS REGARDING NEWBORN SCREENING RE-AUTHORIZATION ACT GENERAL DISCUSSIONS REGARDING THE ORPHAN DRUG ACT GENERAL DISCUSSIONS REGARDING HEALTH CARE FINANCING
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
BIOMARIN PHARMACEUTICAL INC. via BIOMARIN PHARMACEUTICAL INC.
2018 · fourth_quarter · Q4
H.RES. 1154: AFFIRMING THE IMPORTANCE OF THE ORPHAN DRUG ACT, APPLAUDING ITS LIFESAVING CONTRIBUTIONS OVER ITS 35-YEAR HISTORY, AND RECOGNIZING THE NEED TO CONTINUE SUPPORTING RESEARCH AND DEVELOPMENT FOR RARE DISEASES; ALL PROVISIONS OF THE RESOLUTION GENERAL DISCUSSIONS REGARDING GENE THERAPY GENERAL DISCUSSIONS REGARDING PHENYLKETONURIA(PKU) EDUCATION AND OUTREACH GENERAL DISCUSSIONS REGARDING THE ORPHAN DRUG ACT GENERAL DISCUSSIONS REGARDING NEWBORN SCREENING GENERAL DISCUSSION REGARDING ADVANCE NOTICE OF PROPOSED RULE MAKING (ANPRM): INTERNATIONAL PRICING INDEX MODEL FOR MEDICARE PART B DRUGS GENERAL DISCUSSIONS REGARDING HEALTH EDUCATION
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
BIOMARIN PHARMACEUTICAL INC. via BIOMARIN PHARMACEUTICAL INC.
2018 · third_quarter · Q3
H.R. 6801: RARE DISEASE FUND (RaD) ACT OF 2018; ALL PROVISION OF THE BILL GENERAL DISCUSSIONS REGARDING GENE THERAPY GENERAL DISCUSSIONS REGARDING PHENYLKETONURIA(PKU) EDUCATION AND OUTREACH GENERAL DISCUSSIONS REGARDING IMPACT OF FOOD AND DRUG ADMINISTRATION REORGANIZATION ON RARE DISEASE CLINICAL GENERAL DISCUSSIONS REGARDING AMERICAN PATIENTS FIRST: BLUEPRINT TO LOWER DRUG PRICES AND REDUCE OUT OF POCKET COSTS
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
BIOMARIN PHARMACEUTICAL INC. via BIOMARIN PHARMACEUTICAL INC.
2018 · second_quarter · Q2
H.R. 5247: TRICKETT WENDLER, FRANK MONGIELLO, JORDAN MCLINN, AND MATTHEW BELLINA RIGHT TO TRY ACT OF 2018; ALL PROVISIONS OF THE BILL H.R. 5115: RARE dISEASE ADVANCEMENT, RESEARCH, AND EDUCATION (RARE) ACT OF 2018; ALL PROVISIONS OF THE BILL S. 204: TRICKETT WENDLER, FRANK MONGIELLO, JORDAN MCLINN, AND MATTHEW BELLINA RIGHT TO TRY ACT OF 2017; ALL PROVISIONS OF THE BILL GENERAL DISCUSSIONS REGARDING PRESERVATION OF ORPHAN DRUG ACT GENERAL DISCUSSIONS REGARDING FOOD AND DRUG ADMINISTRATION DISEASE EDUCATION GENERAL DISCUSSIONS REGARDING GENE THERAPY, RARE BRAIN DISORDER, FOOD AND DRUG ADMINISTRATION ADVISORY COMMITTEE MEETINGS AND PRESCRIPTION DRUG COST
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
BIOMARIN PHARMACEUTICAL INC. via BIOMARIN PHARMACEUTICAL INC.
2018 · first_quarter · Q1
H.R. 5247: TRICKETT WENDLER, FRANK MONGIELLO, JORDAN MCLINN, AND MATTHEW BELLINA RIGHT TO TRY ACT OF 2018; ALL PROVISIONS OF THE BILL S. 204: TRICKETT WENDLER, FRANK MONGIELLO, JORDAN MCLINN, AND MATTHEW BELLINA RIGHT TO TRY ACT OF 2017; ALL PROVISIONS OF THE BILL ORPHAN DRUG ACT (NO BILL); PROVISIONS RELATED TO ORPHAN DRUG CREDIT, EXCLUSIVITY, DESIGNATION, AND EDUCATION
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
BIOMARIN PHARMACEUTICAL INC. via BIOMARIN PHARMACEUTICAL INC.
2017 · fourth_quarter · Q4
H.R. 1: AN ACT TO PROVIDE FOR RECONCILIATION PURSUANT TO TITLES II AND V OF THE CONCURRENT RESOLUTION ON THE BUDGET FOR FISCAL YEAR 2018; PROVISIONS RELATED TO THE ORPHAN DRUG TAX CREDIT S. 204: TRICKETT WENDLER, FRANK MONGIELLO, JORDAN MCLINN, AND MATTHEW BELLINA RIGHT TO TRY ACT OF 2017; PROVISIONS RELATED TO EXPANDED ACCESS, USE OF OUTCOMES AND LANGUAGE
Filing targets: HOUSE OF REPRESENTATIVES, Office of the Vice President of the United States, SENATE
BIOMARIN PHARMACEUTICAL INC. via BIOMARIN PHARMACEUTICAL INC.
2017 · third_quarter · Q3
H.R.878: RIGHT TO TRY ACT OF 2017; PROVISIONS RELATED TO EXPANDED ACCESS AND USE OF OUTCOMES. H.R. 1628: AMERICAN HEALTH CARE ACT OF 2017 (SENATE DRAFT: BETTER CARE RECONCILIATION ACT OF 2017); PROVISIONS RELATED TO MEDICAID, BLOCK GRANTS AND WAIVERS FOR ESSENTIAL HEALTH BENEFITS. H.R. 2430: FDA REAUTHORIZATION ACT OF 2017; ALL PROVISIONS OF THE BILL. S. 204: TRICKETT WENDLER, FRANK MOGIELLO, JORDAN MCLINN AND MATTHEW BELLINA RIGHT TO TRY ACT OF 2017; PROVISIONS RELATED TO EXPANDED ACCESS, USE OF OUTCOMES AND LANGUAGE. S. 586: CORPORATE TAX DODGING PREVENTION ACT; PROVISIONS RELATED TO MEDICAID AND BLOCK GRANTS. S 934: FDA REAUTHORIZATION ACT OF 2017; PROVISIONS RELATED TO ORPHAN DRUGS AND EXPANDED ACCESS.
GENERAL DISCUSSIONS REGARDING TAX REFORM AND THE ORPHAN DRUG TAX CREDIT.
Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, SENATE
BIOMARIN PHARMACEUTICAL INC. via BIOMARIN PHARMACEUTICAL INC.
2017 · second_quarter · Q2
H.R. 1628: AMERICAN HEALTH CARE ACT OF 2017; ALL PROVISIONS OF THE BILL H.R. 2430: FDA REAUTHORIZATION ACT OF 2017; PROVISIONS RELATED TO ORPHAN DRUG ACT, RIGHT TO TRY AND RACE ACT S 934: FDA REAUTHORIZATION ACT OF 2017; PROVISIONS RELATED TO ORPHAN DRUG ACT, RIGHT TO TRY AND RACE ACT DRAFT BILL: BETTER CARE RECONCILIATION ACT; PROVISIONS RELATED TO MEDICAID AND WAIVERS FOR ESSENTIAL HEALTH BENEFITS DISCUSSIONS REGARDING THE ORPHAN DRUG ACT; PROVISIONS RELATED TO VALUE OF RARE DISEASE THERAPIES
Filing targets: HOUSE OF REPRESENTATIVES, Office of the Vice President of the United States, SENATE
BIOMARIN PHARMACEUTICAL INC. via BIOMARIN PHARMACEUTICAL INC.
2017 · first_quarter · 1A
GENERAL DISCUSSION REGARDING THE PRESERVATION OF SECTION 45C OF THE INTERNAL REVENUE CODE. GENERAL DISCUSSION REGARDING TAX CREDITS.
H.R. 1628: AMERICAN HEALTH CARE ACT OF 2017; PROVISIONS RELATED TO MEDICAID FUNDING. SPIKE ACT OF 2017 (DRAFT BILL): PROVISIONS RELATED TO PRESCRIPTION DRUG TRANSPARENCY. GENERAL DISCUSSION REGARDING PRODUCT LAUNCH. GENERAL DISCUSSION REGARDING THE ORPHAN DRUG ACT. GENERAL DISCUSSION REGARDING ACCELERATED APPROVAL FOR SOMATIC CELL GENE THERAPY.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
BIOMARIN PHARMACEUTICAL INC. via BIOMARIN PHARMACEUTICAL INC.
2017 · first_quarter · Q1
H.R. 1628: AMERICAN HEALTH CARE ACT OF 2017; PROVISIONS RELATED TO MEDICAID FUNDING. SPIKE ACT OF 2017 (DRAFT BILL): PROVISIONS RELATED TO PRESCRIPTION DRUG TRANSPARENCY. GENERAL DISCUSSION REGARDING PRODUCT LAUNCH. GENERAL DISCUSSION REGARDING THE ORPHAN DRUG ACT. GENERAL DISCUSSION REGARDING ACCELERATED APPROVAL FOR SOMATIC CELL GENE THERAPY.
GENERAL DISCUSSION REGARDING THE PRESERVATION OF SECTION 45C OF THE INTERNAL REVENUE CODE. GENERAL DISCUSSION REGARDING TAX CREDITS.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
BIOMARIN PHARMACEUTICAL INC. via BIOMARIN PHARMACEUTICAL INC.
2016 · fourth_quarter · Q4
H.R. 6: 21ST CENTURY CURES ACT; PROVISIONS RELATED TO RARE PEDIATRIC DISEASE PRIORITY REVIEW VOUCHER PROGRAM H.R. 34: 21ST CENTURY CURES ACT; PROVISIONS RELATED TO RARE PEDIATRIC DISEASE PRIORITY REVIEW VOUCHER PROGRAM EXTENSION, REGENERATIVE MEDICINE, PATIENT EXPERIENCE DATA, AND REAL WORLD EVIDENCE DATA H.R. 971: ORPHAN PRODUCT EXTENSIONS NOW ACCELERATING CURES AND TREATMENTS ACT OF 2015; PROVISIONS RELATED TO PATENT EXTENSION H.R. 1537: ADVANCING HOPE ACT OF 2015; PROVISIONS RELATED TO RARE PEDIATRIC DISEASE PRIORITY REVIEW VOUCHER PROGRAM EXTENSION H.R. 3742: ACCESS TO MARKETPLACE INSURANCE ACT: PROVISIONS RELATED TO THIRD PARTY PREMIUM ASSISTANCE S 275: MEDICARE HOME INFUSION SITE OF CARE ACT OF 2015; PROVISIONS RELATED TO HOME INFUSION BENEFIT S 1421: ORPHAN PRODUCT EXTENSIONS NOW ACCELERATING CURES AND TREATMENTS ACT OF 2015; PROVISIONS RELATED TO PATENT EXTENSION S 1597: PATIENT-FOCUSED IMPACT ASSESSMENT ACT OF 2016; PROVISIONS RELATED TO PATIENT ENGAGEMENT AND FOOD AND DRUG ADMINISTRATION REQUIREMENTS S 1767: COMBINATION PRODUCT REGULATORY FAIRNESS ACT OF 2016; PROVISIONS RELATED TO COMBINATION PRODUCT REVIEW S 1878: ADVANCING HOPE ACT OF 2016; PROVISIONS RELATED TO RARE PEDIATRIC DISEASE PRIORITY REVIEW VOUCHER PROGRAM EXTENSION
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
BIOMARIN PHARMACEUTICAL INC. via BIOMARIN PHARMACEUTICAL INC.
2016 · third_quarter · Q3
H.R. 6: 21ST CENTURY CURES ACT; PROVISIONS RELATED TO RARE PEDIATRIC DISEASE PRIORITY REVIEW VOUCHER PROGRAM H.R. 3012: RIGHT TO TRY ACT OF 2015; PROVISIONS RELATED TO THE RIGHT TO TRY H.R. 3742: ACCESS TO MARKETPLACE INSURANCE ACT; PROVISIONS RELATED TO PATIENT ASSISTANCE S 1767: COMBINATION PRODUCT REGULATORY FAIRNESS ACT OF 2016; PROVISIONS RELATED TO REGULATION OF COMBINATION PRODUCTS S 1878: ADVANCING HOPE ACT OF 2016; ALL PROVISIONS OF THE BILL S 2912: TRICKETT WENDLER RIGHT TO TRY ACT OF 2016; PROVISIONS RELATED TO RIGHT TO TRY
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
BIOMARIN PHARMACEUTICAL INC. via BIOMARIN PHARMACEUTICAL INC.
2016 · second_quarter · Q2
H.R. 6: 21ST CENTURY CURES ACT; PROVISIONS RELATED TO RARE PEDIATRIC DISEASE PRIORITY REVIEW VOUCHER PROGRAM S 1878: ADVANCING HOPE ACT OF 2016; ALL PROVISIONS OF THE BILL S 2030: ADVANCING TARGETED THERAPIES FOR RARE DISEASES ACT OF 2016; PROVISIONS RELATED TO PERSONALIZED MEDICINE GENERAL DISCUSSION REGARDING ORPHAN DRUG ACT PRESERVATION GENERAL DISCUSSION REGARDING THE SENATE INNOVATION ACT AND THE PRIORITY REVIEW VOUCHER PROGRAM
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
BIOMARIN PHARMACEUTICAL INC. via BIOMARIN PHARMACEUTICAL INC.
2016 · first_quarter · Q1
S 1878: ADVANCING HOPE ACT OF 2016; ALL PROVISIONS OF THE BILL S 2030: ADVANCING TARGETED THERAPIES FOR RARE DISEASES ACT OF 2016; ALL PROVISIONS OF THE BILL
Filing targets: SENATE
BIOMARIN PHARMACEUTICAL INC. via BIOMARIN PHARMACEUTICAL INC.
2015 · fourth_quarter · Q4
HR 6: 21ST CENTURY CURES ACT; PROVISIONS RELATED TO RARE PEDIATRIC DISEASE PRIORITY REVIEW VOUCHER PROGRAM AND PRECISION MEDICINE HR 546: ADVANCING CARE FOR EXCEPTIONAL KIDS(ACE)ACT OF 2015; ALL PROVISIONS OF THE BILL HR 971: ORPHAN PRODUCT EXTENSIONS NOW ACCELERATING CURES AND TREATMENTS ACT OF 2015; PROVISIONS RELATED TO ORPHAN DRUG TAX CREDIT EXCLUSIVITY S 320: MEDICAL INNOVATION ACT OF 2015; PROVISIONS RELATED TO PLATFORM TECHNOLOGIES AND RARE PEDIATRIC DISEASE PRIORITY REVIEW VOUCHER PROGRAM S 1421: ORPHAN PRODUCT EXTENSIONS NOW ACCELERATING CURES AND TREATMENTS ACT OF 2015; PROVISIONS RELATED TO ORPHAN DRUG TAX CREDIT EXCLUSIVITY S 1878: ADVANCING HOPE ACT OF 2015; ALL PROVISIONS OF THE BILL S 2030: ADVANCING TARGETED THERAPIES FOR RARE DISEASES ACT OF 2015; ALL PROVISIONS OF THE BILL
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
BIOMARIN PHARMACEUTICAL INC. via BIOMARIN PHARMACEUTICAL INC.
2015 · third_quarter · Q3
HR 6: 21ST CENTURY CURES ACT; PROVISIONS RELATED TO RARE PEDIATRIC DISEASE PRIORITY REVIEW VOUCHER PROGRAM AND PRECISION MEDICINE S 320: MEDICAL INNOVATION ACT OF 2015; PROVISIONS RELATED TO PLATFORM TECHNOLOGIES AND RARE PEDIATRIC DISEASE PRIORITY REVIEW VOUCHER PROGRAM S 1878: ADVANCING HOPE ACT OF 2015; ALL PROVISIONS OF THE BILL S 2030: ADVANCING TARGETED THERAPIES FOR RARE DISEASES ACT OF 2015; ALL PROVISIONS OF THE BILL
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
BIOMARIN PHARMACEUTICAL INC. via BIOMARIN PHARMACEUTICAL INC.
2015 · second_quarter · Q2
HR 6: 21ST CENTURY CURES ACT; PROVISIONS RELATED TO PEDIATRIC RARE DISEASE PRIORITY REVIEW VOUCHER REVIEW/APPROVAL PROTOCOLS HR 971: ORPHAN PRODUCT EXTENSIONS NOW ACCELERATING CURES AND TREATMENTS ACT OF 2015; PROVISIONS RELATED TO ORPHAN DRUG TAX CREDIT EXCLUSIVITY S 1421: ORPHAN PRODUCT EXTENSIONS NOW ACCELERATING CURES AND TREATMENTS ACT OF 2015; PROVISIONS RELATED TO ORPHAN DRUG TAX CREDIT EXCLUSIVITY S 1597: PATIENT-FOCUSED IMPACT ASSESSMENT ACT OF 2015; PROVISIONS RELATED TO PATIENT-FOCUSED DRUG DEVELOPMENT TOOLS
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
BIOMARIN PHARMACEUTICAL INC. via BIOMARIN PHARMACEUTICAL INC.
2015 · first_quarter · Q1
DISCUSSIONS REGARDING THE 21ST CENTURY CURES DRAFT LEGISLATION AND NON-DISCRIMINATION ISSUES DISCUSSIONS REGARDING MAKING PERMANENT THE FEDERAL DRUG ADMINISTRATION'S PRIORITY REVIEW VOUCHER SYSTEM
DISCUSSIONS REGARDING ISSUES RELATED TO THE ORPHAN DRUG TAX CREDIT
Filing targets: HOUSE OF REPRESENTATIVES
BIOMARIN PHARMACEUTICAL INC. via BIOMARIN PHARMACEUTICAL INC.
2014 · fourth_quarter · Q4
DISCUSSIONS REGARDING CHAIRMAN CAMP'S TAX REFORM DRAFT AND ISSUES RELATED TO THE ORPHAN DRUG TAX CREDIT
HR 5435: MEDICARE HOME INFUSION SITE OF CARE ACT OF 2014; PROVISIONS RELATED TO HOME INFUSION ISSUES DISCUSSIONS REGARDING AFFORDABLE CARE ACT IMPACTS AND NON-DISCRIMINATION DISCUSSIONS REGARDING 21ST CENTURY CURES DRAFT LEGISLATION; PROVISIONS RELATED TO INCENTIVES DISCUSSIONS REGARDING GENE-THERAPY
Filing targets: HOUSE OF REPRESENTATIVES
BIOMARIN PHARMACEUTICAL INC. via BIOMARIN PHARMACEUTICAL INC.
2014 · third_quarter · Q3
DISCUSSIONS REGARDING AFFORDABLE CARE ACT IMPACTS AND NON-DISCRIMINATION DISCUSSIONS REGARDING 21ST CENTURY CURES DRAFT LEGISLATION; PROVISIONS RELATED TO INCENTIVES
DISCUSSIONS REGARDING CHAIRMAN CAMP'S TAX REFORM DRAFT AND ISSUES RELATED TO THE ORPHAN DRUG TAX CREDIT
Filing targets: HOUSE OF REPRESENTATIVES
BIOMARIN PHARMACEUTICAL INC. via BIOMARIN PHARMACEUTICAL INC.
2014 · second_quarter · Q2
DISCUSSIONS RELATED TO ORPHAN DRUG TAX CREDIT
DISCUSSIONS REGARDING COST SHARING
Filing targets: HOUSE OF REPRESENTATIVES
BIOMARIN PHARMACEUTICAL INC. via BIOMARIN PHARMACEUTICAL INC.
2014 · first_quarter · Q1
DISCUSSIONS REGARDING TAX CREDIT AND AFFORDABLE CARE ACT IMPACTS
Filing targets: HOUSE OF REPRESENTATIVES
BIOMARIN PHARMACEUTICAL INC. via BIOMARIN PHARMACEUTICAL INC.
2013 · fourth_quarter · Q4
DISCUSSIONS REGARDING IMPACT OF HEALTHCARE REFORM ON PATIENT'S OUT OF POCKET COSTS WHEN UTILIZING OUT OF NETWORK SERVICES
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
BIOMARIN PHARMACEUTICAL INC. via BIOMARIN PHARMACEUTICAL INC.
2013 · third_quarter · Q3
DISCUSSION REGARDING THE ISSUE OF COMPASSIONATE USE OF PREAPPROVED PRODUCTS
GENERAL DISCUSSIONS RELATED TO ORPHAN DRUG TAX CREDIT
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
BIOMARIN PHARMACEUTICAL INC. via BIOMARIN PHARMACEUTICAL INC.
2013 · second_quarter · Q2
GENERAL DISCUSSIONS RELATED TO ORPHAN DRUG TAX CREDIT
GENERAL DISCUSSIONS RELATED TO FEDERAL HEALTH INSURANCE EXCHANGES
Filing targets: HOUSE OF REPRESENTATIVES
BIOMARIN PHARMACEUTICAL INC. via BIOMARIN PHARMACEUTICAL INC.
2013 · second_quarter · RR
Issues and legislation related to the biopharmaceutical industry.
Issues and legislation related to the biopharmaceutical industry.
Issues and legislation related to the biopharmaceutical industry.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, SENATE
H.R. 4225: A BILL FOR THE RELIEF OF MARIA ISABEL BUESO BARRERA, ALBERTO BUESO MENDOZA, KARLA MARIA BARRERA DE BUESO AND ANA LUCIA BUESO BARRERA; PROVISIONS RELATED TO EXTEND DEFERRED PROGRAM S 2612: A BILL FOR THE RELIEF OF MARIA ISABEL BUESO BARRERA, ALBERTO BUESO MENDOZA AND KARLA MARIA BARRERA DE BUESO; PROVISIONS RELATED TO EXTEND DEFERRED PROGRAM
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
Issues and legislation related to the biopharmaceutical industry.
Issues and legislation related to the biopharmaceutical industry.
Issues and legislation related to the biopharmaceutical industry.